0001104659-20-092988.txt : 20200811 0001104659-20-092988.hdr.sgml : 20200811 20200811063259 ACCESSION NUMBER: 0001104659-20-092988 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 55 CONFORMED PERIOD OF REPORT: 20200630 FILED AS OF DATE: 20200811 DATE AS OF CHANGE: 20200811 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Affimed N.V. CENTRAL INDEX KEY: 0001608390 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: 2M FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36619 FILM NUMBER: 201091009 BUSINESS ADDRESS: STREET 1: IM NEUENHEIMER FELD 582, 69120 CITY: HEIDELBERG STATE: 2M ZIP: 000000 BUSINESS PHONE: 49-6221-65307 MAIL ADDRESS: STREET 1: IM NEUENHEIMER FELD 582, 69120 CITY: HEIDELBERG STATE: 2M ZIP: 000000 FORMER COMPANY: FORMER CONFORMED NAME: Affimed Therapeutics B.V. DATE OF NAME CHANGE: 20140516 6-K 1 a20-26176_16k.htm 6-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549
__________________

FORM 6-K
__________________

Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For the month of August, 2020

Commission File Number: 001-36619

__________________

Affimed N.V.

__________________

Im Neuenheimer Feld 582,
69120 Heidelberg,
Germany

(Address of principal executive offices)

__________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x Form 40-F o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o

INCORPORATION BY REFERENCE

Exhibits 99.1 and 99.2 to this Report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form F-3 (Registration Number 333-227933) and Form S-8 (Registration Numbers 333-198812) of Affimed N.V. and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

Exhibit 99.3 to this Report on Form 6-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in Heidelberg, Germany, August 11, 2020.

	AFFIMED N.V.

	By:	/s/ Adi Hoess
	Name: Adi Hoess
	Title: Chief Executive Officer

	By:	/s/ Angus Smith
	Name: Angus Smith
	Title: Chief Financial Officer

EXHIBIT INDEX

Exhibit		Description of Exhibit
99.1		Affimed N.V. Unaudited Condensed Consolidated Interim Financial Statements as of June 30, 2020
99.2		Affimed N.V. Management’s Discussion and Analysis of Financial Condition and Results of Operations
99.3		Affimed N.V. Press Release dated August 11, 2020

EX-99.1 2 a20-26176_1ex99d1.htm EX-99.1

Exhibit 99.1

AFFIMED N.V.

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Affimed N.V.

Unaudited consolidated statements of comprehensive income / (loss)

(in € thousand)

		For the three months ended June 30		For the six months ended June 30
	Note	2020	2019	2020	2019

Revenue	3	2,934	4,008	8,069	15,361

Other income - net		85	197	28	283
Research and development expenses		(11,697)	(11,545)	(23,146)	(19,532)
General and administrative expenses		(2,606)	(2,342)	(6,131)	(4,776)

Operating income / (loss)		(11,284)	(9,682)	(21,180)	(8,664)

Finance income / (costs) - net	4	(954)	(654)	653	180

Income / (loss) before tax		(12,238)	(10,336)	(20,527)	(8,484)

Income taxes		0	(4)	0	(4)

Income / (loss) for the period		(12,238)	(10,340)	(20,527)	(8,488)

Other comprehensive income / (loss)
Items that will not be reclassified to profit or loss
Equity investments at fair value OCI - net change in fair value	5	(71)	(49)	10	24

Other comprehensive income / (loss)		(71)	(49)	10	24

Total comprehensive income / (loss)		(12,309)	(10,389)	(20,517)	(8,464)



Earnings / (loss) per share in € per share		(0.16)	(0.17)	(0.26)	(0.14)
(undiluted = diluted)

Weighted number of common shares outstanding		79,189,686	62,439,363	77,719,793	62,434,734

The Notes are an integral part of these consolidated financial statements.

Affimed N.V.

Consolidated statements of financial position

(in € thousand)

	Note	June 30, 2020	December 31, 2019
		(unaudited)
ASSETS
Non-current assets

Intangible assets		103	137
Leasehold improvements and equipment		2,237	2,291
Long term financial assets	5	3,203	3,193
Right-of-use assets		536	824
		6,079	6,445
Current assets

Cash and cash equivalents		84,584	95,234
Financial assets	6	8,037	8,902
Trade and other receivables		2,027	1,482
Inventories		421	296
		95,069	105,914

TOTAL ASSETS		101,148	112,359

EQUITY AND LIABILITIES
Equity

Issued capital		845	762
Capital reserves		292,720	270,451
Fair value reserves		1,972	1,962
Accumulated deficit		(255,035)	(234,508)
Total equity	7	40,502	38,667

Non current liabilities

Borrowings	10	231	278
Contract liabilities		27,829	37,961
Lease liabilities		95	272
Total non-current liabilities		28,155	38,511

Current liabilities

Trade and other payables		6,606	10,674
Provisions	9	484	517
Borrowings	10	1,039	2,105
Lease liabilities		451	532
Contract liabilities		23,911	21,353
Total current liabilities		32,491	35,181

TOTAL EQUITY AND LIABILITIES		101,148	112,359

The Notes are an integral part of these consolidated financial statements.

Affimed N.V.

Unaudited consolidated statements of cash flows

(in € thousand)

		For the six months ended June 30
	Note	2020	2019
Cash flow from operating activities
Income / (loss) for the period		(20,527)	(8,488)
Adjustments for the period:
- Income taxes		0	4
- Depreciation and amortisation		551	423
- Net gain from disposal of leasehold improvements and equipment		0	(9)
- Share based payments	8	1,410	1,167
- Finance income / costs - net	4	(653)	(180)
		(19,219)	(7,083)
Change in trade and other receivables		(649)	228
Change in inventories		(125)	(70)
Change in other assets		0	(2,586)
Change in trade, other payables, provisions and contract liabilities		(11,757)	(9,484)
Cash used in operating activities		(31,750)	(18,995)
Interest received		276	188
Paid interest		(64)	(134)
Net cash used in operating activities		(31,538)	(18,941)

Cash flow from investing activities
Purchase of intangible assets		(2)	(142)
Purchase of leasehold improvements and equipment		(174)	(755)
Cash paid for investments in financial assets		(8,101)	(35,262)
Cash received from maturity of financial assets		9,088	25,748
Net cash used for investing activities		811	(10,411)

Cash flow from financing activities
Proceeds from issue of common shares		21,785	13
Transaction costs related to issue of common shares		(754)	0
Proceeds from borrowings		0	562
Repayment of lease liabilities		(257)	(206)
Repayment of borrowings	10	(1,128)	(1,649)
Cash flow from financing activities		19,646	(1,280)

Exchange-rate related changes of cash and cash equivalents		431	(210)

Net changes to cash and cash equivalents		(11,081)	(30,632)
Cash and cash equivalents at the beginning of the period		95,234	94,829
Cash and cash equivalents at the end of the period		84,584	63,987

The Notes are an integral part of these consolidated financial statements.

Affimed N.V.

Unaudited consolidated statements of changes in equity

(in € thousand)

Note

Issued capital

Capital
reserves

Fair Value
reserves

Accumulated
deficit

Total equity

Balance as of January 1, 2019

624

239,055

2,594

(202,144)

40,129

Exercise of share based payment awards

Equity-settled share based payment awards

1,167

Loss for the period

(8,488)

Other comprehensive income

Balance as of June 30, 2019

624

240,235

2,618

(210,632)

32,845

Balance as of January 1, 2020

762

270,451

1,962

(234,508)

38,667

Issue of common shares

20,859

20,942

Equity-settled share based payment awards

1,410

Loss for the period

(20,527)

Other comprehensive income

Balance as of June 30, 2020

845

292,720

1,972

(255,035)

40,502

The Notes are an integral part of these consolidated financial statements.

1. Reporting entity

Affimed N.V. is a Dutch company with limited liability (naamloze vennootschap) and has its corporate seat in Amsterdam, the Netherlands. The consolidated financial statements are comprised of Affimed N.V., and its controlled (and wholly owned) subsidiaries Affimed GmbH, Heidelberg, Germany, AbCheck s.r.o., Plzen, Czech Republic, Affimed Inc., Delaware, USA and AbCheck Inc., Delaware, USA (together “Affimed”, the “Company” or the “Group”).

Affimed is a clinical-stage immuno-oncology company focused on discovering and developing highly targeted cancer immunotherapies. The Group’s product candidates represent an innovative approach to cancer treatment that seeks to harness the body’s own immune defenses to fight tumor cells. Affimed has its own research and development programs, strategic collaborations and service contracts, pursuant to which Affimed is performing research services for third parties.

2. Basis of preparation and changes to Group’s accounting policies

Statement of compliance

The interim financial statements for the three and six months ended June 30, 2020 and 2019 have been prepared in accordance with IAS 34 Interim Financial Reporting. The interim financial statements do not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with Affimed N.V.’s annual consolidated financial statements as of December 31, 2019.

The interim financial statements were authorized for issuance by the management board on August 11, 2020.

Critical judgments and accounting estimates

The preparation of the interim financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.

In preparing these interim financial statements, the critical judgments made by management in applying the Company’s accounting policies were the same as those that applied to the consolidated financial statements as of and for the year ended December 31, 2019.

Functional and presentation currency

These interim financial statements are presented in Euro, which is the Company’s functional currency. All financial information presented in Euro has been rounded to the nearest thousand (abbreviated €) or million (abbreviated € million).

Significant accounting policies

The accounting policies applied by the Company in these interim financial statements are the same as those applied by the Company in its consolidated financial statements as of and for the year ended December 31, 2019 with the exception of new amendments to standards and new or amended interpretations applied for the first time as described below.

New standards and interpretations applied for the first time

The following amendments to standards and new or amended interpretations are effective for annual periods beginning on or after January 1, 2020, and have been applied in preparing these financial statements:

Standard/interpretation		Effective Date

Amendments to References to the Conceptional Framework		January 1, 2020
Amendments to IAS 1 and IAS 8: Definition of Material		January 1, 2020
Amendments to IFRS 9, IAS 39 and IFRS 7:
Interest Rate Benchmark Reform		January 1, 2020
Amendments to IFRS 3 Business Combination		January 1, 2020
Amendment to IFRS 16 Leases Covid 19-Related Rent Concessions		June 1, 2020

None of the amendments to standards and new or amended interpretations had a material effect on the interim financial statements.

Fair Value Measurement

All assets and liabilities for which fair value is recognized in the interim financial statements are classified in accordance with the following fair value hierarchy, based on the lowest level input parameter that is significant on the whole for fair value measurement:

· Level 1 – Prices for identical assets or liabilities quoted in active markets (non-adjusted)

· Level 2 – Measurement procedures, in which the lowest level input parameter significant on the whole for fair value measurement is directly or indirectly observable for on the market

· Level 3 – Measurement procedures, in which the lowest level input parameter

significant on the whole for fair value measurement is not directly or indirectly observable for on the market

The carrying amount of all trade and other receivables, certificates of deposit, cash and cash equivalents and trade and other payables is a reasonable approximation of the fair value and, therefore, information about the fair values of those financial instruments has not been disclosed. The measurement of the fair value of the shares held by the group and note disclosure for the fair value of a loan (financial liability) is based on level 2 measurement procedures (see notes 5 and 10).

New standards and interpretations not yet adopted

The following standards, amendments to standards and interpretations are effective for annual periods beginning after December 31, 2019 and have not been applied in preparing these consolidated financial statements.

Standard/interpretation		Effective Date

Amendments to IAS 1 Presentation of Financial Statements:
Classification of Liabilities as Current or Non-current		January 1, 2022
Amendments to IFRS 3 Business Combinations		January 1, 2022
Amendments to IAS 16 Property, Plant and Equipment		January 1, 2022
Amendments to AS 37 Provisions, Contingent Liabilities and Contingent Assets		January 1, 2022
Annual Improvements 2018-2020		January 1, 2022

3. Revenue

Collaboration agreement The Leukemia & Lymphoma Society (LLS)

Affimed is party to a collaboration with LLS to fund the development of specific product candidates (immune cell engagers). Under the terms of the agreement, LLS has agreed to contribute up to $4.4 million contingent upon the achievement of certain milestones.

In the event that the research and development is successful, Affimed must proceed with commercialization of the licensed product. If Affimed decides for business reasons not to continue the commercialization, Affimed must at its option either repay the amount funded or grant a license to LLS to enable LLS to continue with the development program. In addition, LLS is entitled to receive royalties from Affimed based on the Group’s future revenue from any licensed product, with the amount of royalties not to exceed three times the amount funded.

In June 2016, the research funding agreement with LLS was amended to reflect a shift to the development of combination therapeutic approaches so that the milestones now relate primarily to the development of a combination therapy.

During the six months ended June 30, 2020, the Company recognized revenue totalling €0.1 million (2019: €0 million).

Collaboration with Genentech Inc.

In August 2018, Affimed entered into a strategic collaboration agreement with Genentech Inc., headquartered in South San Francisco, USA. Under the terms of the agreement Affimed will develop novel NK cell engager-based immunotherapeutics to treat multiple cancers. The Genentech agreement became effective at the beginning of October 2018. Affimed received $96.0 million (€83.2 million) in initial upfront and committed funding on October 31, 2018.

The Group recognized €2.7 million and €7.6 million as revenue during the three and six months ended June 30, 2020 (2019: €3.7 million and €14.3 million). As of June 30, 2020, contract liabilities of €51.7 million (December 31, 2019: €59.3 million) will be recognized as revenue in subsequent periods.

Under the terms of the agreement, Affimed is eligible to receive up to an additional $5.0 billion over time, including payments upon achievement of specified development, regulatory and commercial milestones. Affimed is also eligible to receive royalties on any potential sales.

Research service agreements

The Group, through its subsidiary AbCheck s.r.o. has entered into certain research service agreements. These research service agreements provide for non-refundable upfront technology access research funding or capacity reservation fees and milestone payments. The Company recognized €0.2 million and €0.4 million as revenue in the three and six months ended June 30, 2020 (2019: €0.3 million and €1.1 million).

Contract balances

The following table provides information about receivables and contract liabilities from contracts with customers.

	June 30, 2020	December 31, 2019

Receivables	45	204

Contract liabilities	51,739	59,314

Amounts of €2,749 and €7,580 recognized in contract liabilities at the beginning of the period have been recognized as revenue during the three and six months ended June 30, 2020.

The remaining performance obligations as of June 30, 2020 are approximately €51.7 million and are expected to be recognized as revenue to a large extent over the next two years.

Disaggregation of revenue

Geographic information
	Three months ended June 30, 2020	Three months ended June 30, 2019	Six months ended June 30, 2020	Six months ended June 30, 2019
Revenue:
Germany	0	0	75	0
Europe	0	325	2	1,077
USA	2,934	3,683	7,992	14,284
	2,934	4,008	8,069	15,361

Major service lines
	Three months ended June 30, 2020	Three months ended June 30, 2019	Six months ended June 30, 2020	Six months ended June 30, 2019
Collaboration revenue	2,793	3,683	7,716	14,284
Service revenue	141	325	353	1,077
	2,934	4,008	8,069	15,361

Timing on revenue recognition
	Three months ended June 30, 2020	Three months ended June 30, 2019	Six months ended June 30, 2020	Six months ended June 30, 2019
Point in time	106	0	283	5,633
Over time	2,828	4,008	7,786	9,728
	2,934	4,008	8,069	15,361

4. Finance income and finance costs

	Three months ended June 30, 2020	Three months ended June 30, 2019	Six months ended June 30, 2020	Six months ended June 30, 2019
Interest SVB Loan Agreement	(59)	(128)	(116)	(283)
Foreign exchange differences	(1,022)	(728)	554	28
Finance cost lease liability	(6)	(6)	(13)	(13)
Other finance income/finance costs	71	208	166	448
Gain from the modification of SVB Loan Agreement (see note 10)	62	0	62	0
Finance income/costs - net	(954)	(654)	653	180

5. Long term financial assets

The Company holds preferred shares in Amphivena recognized at their fair value of €3.2 million (December 31, 2019: €3.2 million). As of June 30, 2020, the fair value increased by €10 as compared to December 31, 2019 due to exchange rate differences recognized in other comprehensive income for the six months ended June 30, 2020 (2019: increase of €24). During the three months ended June 30, 2020 and 2019 the fair value decreased by €71 and €49 due to exchange rate differences.

6. Financial assets

As of June 30, 2020 and December 31, 2019, financial assets consisted of U.S. Dollar denominated certificates of deposit with original maturities of more than three months.

7. Equity

As of June 30, 2020 the share capital of €845 (December 31, 2019: €762) is divided into 84,493,155 (December 31, 2019: 76,249,901) common shares with a par value of €0.01 per share.

In May 2020, the Company implemented an at-the-market (“ATM”) program providing for the sales over time of up to $50,000,000 of its common shares. As of June 30, 2020, the Company has issued approximately 8.1 million common shares under this ATM program, generating net proceeds of approximately €21 million.

8. Share-based payments

In 2014, an equity-settled share-based payment program was established by Affimed N.V. (ESOP 2014). Under this program, the Company granted awards to certain members of the Management Board, the Supervisory Board, non-employee consultants and employees.

Share based payments with service condition

The majority of the awards vest in instalments over three years and can be exercised up to 10 years after the grant date. In the three and six months ended June 30, 2020, the group granted 478,750 and 1,388,559 awards. 58,729 and 183,141 ESOP 2014 awards were cancelled or forfeited, and 197,007 options were exercised during the three and six months ended June 30, 2020. As of June 30, 2020, 8,315,978 ESOP 2014 options (December 31, 2019: 7,307,567) were outstanding, and 5,623,642 awards (December 31, 2019: 4,773,840) had vested. The options outstanding as of June 30, 2020 had an exercise price in the range of $1.30 to $13.47.

Share based payments with market condition

On April 20, 2018, Affimed issued 240,000 options, of which each grant consists of three tranches that vest when the volume-weighted average share price (measured based on Affimed closing share prices over the preceding fifteen trading days) reaches a certain hurdle ($6.15, $8.20 and $10.25). Fair value of the awards at grant date amounts to €133 ($164 thousand) and the contractual life time of the options was two years. No options were exercisable and the term of the options has been expired.

Share based payment expense

In the three and six months ended June 30, 2020, compensation expense of €684 and €1,410 was recognized affecting research and development expenses (€400 and €717) and general and administrative expenses (€284 and €693). In the three and six months ended June 30, 2019, compensation expense of €566 and €1,167 was recognized affecting research and development expenses (€231 and €500) and general and administrative expenses (€335 and €667).

Fair value measurement

The fair value of options was determined using the Black-Scholes valuation model. The

significant inputs into the valuation model of share based payment grants with service conditions are as follows (weighted average):

	June 30, 2020	June 30, 2019

Fair value at grant date	$1.81	$2.11
Share price at grant date	$2.50	$3.04
Exercise price	$2.50	$3.04
Expected volatility	91%	82%
Expected life	5.90	5,83
Expected dividends	0.00	0.00
Risk-free interest rate	1.30%	2.14%

Expected volatility is estimated based on the observed daily share price returns of a peer group measured over a historic period equal to the expected life of the awards.

The risk-free interest rates are based on the yield to maturity of U.S. Treasury strips and German sovereign strips respectively (as best available indication for risk-free rates), for a term equal to the expected life, as measured as of the Grant Date.

9. Provisions

In 2019, the group recognized costs related to the termination of the AFM 11 program totalling to €1.4 million, whereof €0.9 million were already incurred in 2019. Estimated costs expected to be incurred in future periods were recognized in provisions (€0.5 million, December 31, 2019: €0.5 million).

10. Borrowings

Silicon Valley Bank

On November 30, 2016, the Company entered into a loan agreement with Silicon Valley Bank (the “SVB loan”) which provides the Company with a senior secured term loan facility for up to €10.0 million, which agreement was amended in May 2017 to provide that such amount would be available in three tranches. In December 2016, the Company drew an initial tranche of €5.0 million and in May 2017, a second tranche of €2.5 million; the availability of a third tranche of €2.5 million expired in September 2017 with such amount remaining undrawn.

Finance costs comprise the interest rate of one-month EURIBOR plus an applicable margin of 5.5%, with a floor of 5.5%, related one-time legal and arrangement fees of €236 and a final payment fee equal to 10% of the total principal amount to be paid with

the last instalment. Pursuant to the loan agreement, the Company also granted the lender 166,297 and 53,395 warrants with an exercise price of $2.00 and $2.30 per share, respectively. Each warrant can be used to purchase common shares of Affimed at the respective exercise price for a period of ten years from the date of grant. The fair value of the warrants of €192 less deferred taxes and transaction costs of €81 and €8, respectively, was recorded as an addition to capital reserves in the equity of Affimed. The fair value of the warrants was determined using the Black-Scholes-Merton valuation model, with an expected volatility of 75 to 80% and an expected exercise period of five years to exercise of the warrant. The contractual maturity of the warrants is ten years.

The loan is secured by a pledge of 100% of Company’s ownership interest in Affimed GmbH, all intercompany claims owed to Affimed N.V. by its subsidiaries, and collateral agreements for all bank accounts, inventory, trade receivables and other receivables of Affimed N.V. and Affimed GmbH recognized in the consolidated financial statements.

As of June 30, 2020 and December 31, 2019, the fair value of the liability did not differ significantly from its carrying amount (€947 and €2,013). Repayment started in December 2017 with amortized payments of principal and interest in equal monthly instalments. In April 2020, the Company agreed with Silicon Valley Bank to extend the original maturity date of May 31, 2020 by six months to November 30, 2020. The modification resulted in a gain of €62 recognized in finance income. As of June 30, 2020, €947 (December 31, 2019: €2,013) was classified as current liabilities.

UniCredit Leasing CZ

In April 2019, the Group entered into a loan agreement with UniCredit Leasing CZ for €562. After an initial instalment of €127 in the second quarter of 2019, repayment is effected in monthly instalments of €8 until November 2023. As of June 30, 2020, an amount of €323 (December 31, 2019: €368) was outstanding, of which €92 was classified as current liabilities (December 31, 2019: €93). As of June 30, 2020, the fair value of the liability did not differ significantly from its carrying amount.

11. Related parties

The supervisory directors of Affimed N.V. received compensation for their services on the supervisory board of €96 and €181 (€100 and €195) in the three and six months ended June 30, 2020 (2019), remuneration of managing directors and other key management personnel amounted to €593 and €1,198 (€708 and €1,414). The payments in the six months ended June 30, 2020 include payments following the death of our former Chief Financial Officer, Florian Fischer, amounting to €120.

The Company recognized share-based payment expenses of €17 and €53 (€19 and €40) for supervisory directors and €361 and €721 (€320 and €723) for managing directors and other key management personnel in the three and six months ended June 30, 2020 (2019).

The following table provides the outstanding balances for management and supervisory board remuneration.

	Outstanding balances
	June 30, 2020	December 31, 2019
Adi Hoess	0	5
Wolfgang Fischer	0	1
Dr. Thomas Hecht	19	26
Berndt Modig	9	9
Ferdinand Verdonck	11	11
Dr. Ulrich Grau	17	21
Dr. Bernhard Ehmer	16	20
Mathieu Simon	8	9

12. Subsequent events

Upon the achievement of a clinical milestone in July 2020 under its ongoing strategic collaboration with Genentech, Affimed is eligible to receive a payment in an undisclosed amount.

EX-99.2 3 a20-26176_1ex99d2.htm EX-99.2

Exhibit 99.2

AFFIMED N.V.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This management’s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. We recommend that you read this in conjunction with our unaudited interim condensed consolidated financial statements for the three and six month periods ended June 30, 2020 and 2019 included as Exhibit 99.1 to the Report on Form 6-K in which this discussion is included. We also recommend that you read “Item 4. Information on the Company” and our audited consolidated financial statements for fiscal year 2019, and the notes thereto, which appear in our Annual Report on Form 20-F for the year ended December 31, 2019 (the “Annual Report”) filed with the U.S. Securities and Exchange Commission (the “SEC”).

Unless otherwise indicated or the context otherwise requires, all references to “Affimed” or the “company,” “we,” “our,” “ours,” “us” or similar terms refer to Affimed N.V. and its subsidiaries.

We prepare and report our consolidated financial statements and financial information in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (the “IASB”). None of our financial statements were prepared in accordance with generally accepted accounting principles in the United States. Our reporting currency is the Euro. We have made rounding adjustments to some of the figures included in this management’s discussion and analysis. Accordingly, numerical figures shown as totals in some tables may not be an arithmetic aggregation of the figures that precede them. Unless otherwise indicated, all references to currency amounts in this discussions and analysis are in euros.

Overview

We are a clinical-stage immuno-oncology company focused on discovering and developing highly targeted cancer immunotherapies. Our product candidates represent an innovative approach to cancer treatment that seeks to harness the body’s own immune defenses to fight tumor cells. One of the most potent cells of the human defense arsenal are types of white blood cells called innate immune cells (Natural Killer cells, or NK cells, and macrophages). Leveraging our fit-for-purpose ROCK® (Redirected Optimized Cell Killing) platform, we develop proprietary, next-generation bispecific antibodies, so-called innate cell engagers, which are designed to direct innate immune cells and establish a bridge to cancer cells. Our innate cell engagers have the ability to bring innate immune cells into the proximity of tumor cells and trigger a signal cascade that leads to the destruction of cancer cells. Due to their novel tetravalent architecture with four binding domains, our innate cell engagers bind to their targets with high affinity and have half-lives that allow for regular intravenous administration. Different dosing schemes are being explored to allow for improved exposure in relapsed and refractory cancer patient populations. Based on their mechanism of action as well as the preclinical and clinical data we have generated to date, we believe that our product candidates as monotherapy, or in combination, may ultimately improve response rates, clinical outcomes and survival in cancer patients, and could eventually become a cornerstone of modern targeted oncology care. Building on our leadership in the innate cell engager space, we are also developing novel antibody formats with the potential to tailor innate cell-engaging therapy to different indications and settings.

To date, we have financed our operations primarily through our public offerings of our common shares, private placements of equity securities, the incurrence of loans including convertible loans and through government grants and payments for collaborative research and development services. Through June 30, 2020, we have raised an aggregate of approximately €280 million (gross proceeds) through the issuance of equity and incurrence of loans. To date, we have not generated any revenues from product sales or royalties. Based on our current plans, we do not expect to generate product or royalty revenues unless and until we or any collaboration partner obtain marketing approval for, and commercialize, any of our product candidates.

We have generated losses since we began our drug development operations in 2000. As of June 30, 2020, we had an accumulated deficit of €255.0 million.

Notwithstanding our collaboration with Genentech and the income earned for the three and six month periods ended June 30, 2020 and anticipated in the remainder of 2020 upon the achievement of specified milestones, we expect to continue incurring losses as we continue our preclinical and clinical development programs, apply for marketing approval for our product candidates and, subject to obtaining regulatory approval for our product candidates, build a marketing and sales team to commercialize our product candidates. Our profitability is dependent upon the successful development, approval, and commercialization of our product candidates and achieving a level of revenues adequate to support our cost structure. We may never achieve profitability, and unless and until we do, we will continue to need to raise additional cash. We intend to fund future operations through additional equity and debt financings, and we may seek additional capital through arrangements with strategic partners or from other sources.

In 2009, we formed AbCheck, our 100% owned, independently run antibody screening platform company, located in the Czech Republic. AbCheck is devoted to the generation and optimization of fully human antibodies. Its technologies include a naïve human antibody library combined with a phage and yeast display antibody library, a proprietary algorithm to optimize affinity, stability and

manufacturing efficiency and a mass humanization technology to discover and optimize high-quality human antibodies. In addition to providing candidates for Affimed projects, AbCheck is recognized for its expertise in antibody discovery throughout the United States and Europe and has been working with globally active pharmaceutical and biotechnology companies such as Tusk Therapeutics, bluebird bio, Eli Lilly, Daiichi Sankyo, Pierre Fabre and others.

We have one U.S. subsidiary, Affimed Inc., with senior employees in finance, investor relations, business development, corporate strategy and clinical operations.

Recent Developments

The Company announced in early February 2020 that Dr. Florian Fischer, Chief Financial Officer (“CFO”) of Affimed, passed away. In June 2020, the Company announced the appointment of Angus Smith as Affimed’s new permanent CFO, completing Affimed’s leadership team. Mr. Smith started his employment on July 13, 2020 and is based out of Affimed’s New York office. In addition, the Company announced the employment of Dr. Andreas Harstrick as Chief Medical Officer, starting in March 2020, and of Dr. Arndt Schottelius as Chief Scientific Officer, effective April 2020.

In May 2020, the Company implemented an at-the-market (“ATM”) program providing for the sales over time of up to $50,000,000 of its common shares. The offering is conducted under the Company’s effective shelf registration statement on Form F-3 pursuant to a prospectus supplement and the entry into a sales agreement with Jefferies LLC. As of June 30, 2020, the Company has issued approximately 8.1 million common shares under the ATM program, generating net proceeds of approximately $23.1 million.

As circumstances around the COVID-19 pandemic continue to rapidly evolve, Affimed is continuously assessing possible effects on its clinical trials and adapting the risk mitigation measures it has implemented. Affimed is closely monitoring and adhering to relevant federal and local guidelines on COVID-19 to ensure the safety and health of its global workforce and help limit the spread of COVID-19, while maintaining business continuity. The Company has taken mitigation steps to ensure that drug supply and other trial-related materials are ready and available for the patients enrolled in its clinical trials. The Company continues to evaluate the potential impact of the COVID-19 pandemic on patient enrollment and site activation in its clinical studies. Timelines for clinical studies presented herein and in our press release for the second quarter of 2020 represent the Company’s best estimates as of the date hereof, but remain subject to change pending the resolution of the COVID-19 crisis.

At the Annual General Meeting held on August 4, 2020, the shareholders of Affimed approved all agenda items, including the reappointment of Supervisory Directors, Dr. Thomas Hecht and Ferdinand Verdonck and the appointment of new Supervisory Directors, Dr. Annalisa Jenkins and Harry Welten. In addition, the shareholders approved the reappointment of Managing Directors, Dr. Adi Hoess and Dr. Wolfgang Fischer and the appointment of Dr. Arndt Schottelius, Dr. Andreas Harstrick and Angus Smith.

Upon the achievement of a clinical milestone in July 2020 under its ongoing strategic collaboration with Genentech, Affimed is eligible to receive a payment in an undisclosed amount.

Collaboration and License Agreements

There have been no material changes to our license agreements from those reported in “Item 4. Information on the Company—B. Business Overview—Collaborations” in the Annual Report.

Research and Development Expense

We will use our existing liquidity primarily to fund research and development expense. Our research and development expense is highly dependent on the development phases of our research projects and therefore fluctuates highly from period to period. Our research and development expense mainly relates to the following key programs:

· AFM13. In November 2019, we initiated a registration directed phase 2 study of AFM13 as monotherapy in relapsed or refractory patients suffering from peripheral T cell lymphoma (pTCL). The study protocol has been agreed upon with the U.S. Food and Drug Administration (FDA). The study design follows a 2 stage Simon design with a preplanned interim analysis after 40 patients. At the current recruitment rate the Company expects the readout of the interim analysis to happen in mid-2021. In addition, this study will, as a separate cohort, investigate the initial efficacy of AFM13 as monotherapy in patients suffering from transformed mycosis fungoides (T-MF), though this cohort is on hold pending the resolution of the COVID-19 pandemic. In September 2019, the FDA cleared an investigational new drug application (IND) for an investigator-sponsored Phase 1 study, in which the University of Texas MD Anderson Cancer Center (MDACC) plans to investigate the combination of AFM13 with allogeneic NK cells. MDACC intends to administer a stable complex of AFM13 pre-mixed with cord blood-derived allogeneic NK cells in different doses (numbers of pre-loaded NK cells) into patients with relapsed/refractory CD30-positive lymphoid malignancies. In 2017, an investigator-

sponsored Phase 1b/2a study was initiated by Columbia University to investigate AFM13 as monotherapy in patients with relapsed or refractory CD30-positive lymphoma with cutaneous manifestation. In 2016, we initiated a phase 1b study investigating the combination of AFM13 with Merck’s anti-PD1 antibody Keytruda® (pembrolizumab) in patients with relapsed/refractory HL. In this study, enrollment is complete and final data were recently presented. Different dosing protocols are being explored in the investigator-initiated monotherapeutic phase 2a clinical trial of AFM13 in relapsed/refractory Hodgkin Lymphoma, or relapsed/refractory HL, to allow for improved exposure in more heavily pretreated patient populations. The study has now completed recruitment under the new study design. We anticipate that our research and development expenses in 2020 for AFM13 will increase compared to those for 2019 due to the initiation of new clinical studies, pre-clinical studies with collaboration partners and the preparation of the production of AFM13 for commercial purposes.

· AFM11. In line with the strategic focus on our innate cell engager portfolio, we have made the decision to terminate the Phase 1 clinical program of AFM11. This decision took into consideration the competitive landscape of B-cell directed therapies currently in development and associated resources needed for further development of AFM11. We subsequently informed the FDA of our intention to terminate the clinical program.

· AFM24. AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, is in effect for a phase 1/2a clinical trial in patients with advanced cancers known to express EGFR. We anticipate that our research and development expenses in the remainder of 2020 for AFM24 will increase compared to those for 2019 due to the beginning of the clinical trial of AFM24 in patients.

· Other projects and infrastructure costs. Our other research and development expenses relate to our Genentech collaboration, Affimed owned preclinical programs (AFM28 and AFM32) and early stage development/discovery activities. We have allocated a material amount of our resources to such discovery activities. The expenses mainly consist of salaries, manufacturing costs for pre-clinical study material and pre-clinical studies. In addition, we incur a significant amount of costs associated with our research and development that are non-project specific, including intellectual property-related expenses, depreciation expenses and facility costs. Because these are less dependent on individual ongoing programs, they are not allocated to specific projects. We assume that other projects and infrastructure costs will increase in the remainder of 2020 due to increased early stage development/discovery activities.

Results of Operations

The financial information shown below was derived from our unaudited interim condensed consolidated financial statements for the three and six month periods ended June 30, 20120 and 2019. The discussion below should be read along with these financial statements, and it is qualified in its entirety by reference to them.

Comparison of the three months ended June 30, 2020 and 2019

	Three months ended June 30,
	2020	2019
	(unaudited)
	(in €thousand)

Total Revenue:	2,934	4,008
Other income (expenses)—net	85	197
Research and development expenses	(11,697)	(11,545)
General and administrative expenses	(2,606)	(2,342)
Operating loss	(11,284)	(9,682)
Finance income/(costs)—net	(954)	(654)
Loss before tax	(12,238)	(10,336)
Income taxes	(0)	(4)
Loss for the period	(12,238)	(10,340)
Other comprehensive income	(71)	(49)
Total comprehensive loss	(12,309)	(10,389)
Loss per common share in € per share (undiluted)	(0.16)	(0.17)
Loss per common share in € per share (diluted)	(0.16)	(0.17)

Revenue

Revenue decreased to €2.9 million in the three months ended June 30, 2020 from €4.0 million for the three months ended June 30, 2019. Revenue in the three months ended June 30, 2020 predominantly relates to the Genentech collaboration (€2.7 million, 2019: €3.7 million). Revenue from the Genentech collaboration in the three months ended June 30, 2020 was recognized for collaborative research services performed during the quarter.

Research and development expenses

	Three months ended June 30,
R&D Expenses by Project	2020	2019	Change %
	(unaudited)
	(in € thousand)

Project
AFM13	5,903	3,965	49%
AFM11	(99)	1,637	-
AFM24	1,005	1,034	(3%)
Other projects and infrastructure costs	4,488	4,678	(4%)
Share-based payment expense	400	231	73%
Total	11,697	11,545	1%

Research and development expenses amounted to €11.7 million in the three months ended June 30, 2020 compared to research and development expenses of €11.5 million in the three months ended June 30, 2019. The variances in project-related expenses between the three months ended June 30, 2020 and the corresponding period in 2019 are mainly due to the following projects:

· AFM13. In the three months ended June 30, 2020, we incurred higher expenses (49%) than in the three months ended June 30, 2019 primarily due to higher expenses for the preparation of new clinical trials and manufacturing activities for clinical trial material.

· AFM11. In the three months ended June 30, 2020, we recognized refunds from service providers following the termination of clinical trials. Expenses in the three months ended June 30, 2019 primarily consist of accrued costs for the termination of the phase 1 clinical program of AFM11.

· AFM24. In the three months ended June 30, 2020, expenses were nearly unchanged and related to the initiation of the phase 1/2a clinical trial and manufacturing activities for the clinical trial material.

· Other projects and infrastructure costs. In the three months ended June 30, 2020, expenses were slightly lower (4%) than in the three months ended June 30, 2019. Expenses related to our discovery/early stage development activities and infrastructure costs.

General and administrative expenses

General and administrative expenses were higher and amounted to €2.6 million in the three months ended June 30, 2020 compared to €2.3 million in the three months ended June 30, 2019.

Finance income / (costs)-net

Finance costs for the three months ended June 30, 2020 totaled €1.0 million, compared to €0.7 million for the three months ended June 30, 2019. Finance costs in the three months ended June 30, 2020 and 2019 primarily include foreign exchange losses.

Comparison of the six months ended June 30, 2020 and 2019

	Six months ended June 30,
	2020	2019
	(unaudited)
	(in € thousand)

Total Revenue:	8,069	15,361
Other income/(expenses)—net	28	283
Research and development expenses	(23,146)	(19,532)
General and administrative expenses	(6,131)	(4,776)
Operating loss	(21,180)	(8,664)
Finance income/(costs)—net	653	180
Loss before tax	(20,527)	(8,484)
Income taxes	0	(4)
Loss for the period	(20,527)	(8,488)
Other comprehensive income	10	24
Total comprehensive loss	(20,517)	(8,464)
Loss per common share in € per share (undiluted)	(0.26)	(0.14)
Loss per common share in € per share (diluted)	(0.26)	(0.14)

Revenue

Revenue decreased from €15.4 million in the six months ended June 30, 2019 to €8.1 million for the six months ended June 30, 2020. Revenue in the six months ended June 30, 2020 predominantly relate to the Genentech collaboration (€7.6 million, 2019: €14.3 million). Revenue from the Genentech collaboration in the six months ended June 30, 2020 was recognized for collaborative research services performed during the first half of the year, while revenue in the in the six months ended June 30, 2019 was recognized for collaborative research services and the achievement of a preclinical milestone.

Research and development expenses

	Six months ended June 30,
R&D Expenses by Project	2020	2019	Change %
	(unaudited)
	(in € thousand)

Project
AFM13	11,186	6,608	69%
AFM11	(77)	1,995	-
AFM24	2,514	2,086	21%
Other projects and infrastructure costs	8,806	8,343	6%
Share-based payment expense	717	500	43%
Total	23,146	19,532	19%

Research and development expenses increased from €19.5 million in the six months ended June 30, 2019 to €23.1 million in the six months ended June 30, 2020. The variances in project-related expenses between the six months ended June 30, 2020 and the corresponding period in 2019 are mainly due to the following projects:

· AFM13. In the six months ended June, 2020, we incurred significantly higher expenses (69%) than in the six months ended June 30, 2019 primarily due to higher expenses for the preparation of new clinical trials and manufacturing activities for clinical trial material.

· AFM11. In the six months ended June 30, 2020, we recognized refunds from service providers following the termination of clinical trials. The majority of the expenses in the six months ended June 30, 2019 are related to costs for the termination of the phase 1 clinical program of AFM11.

· AFM24. In the six months ended June 30, 2020, we incurred higher expenses due to the initiation of the phase 1/2a clinical trial and manufacturing activities for the clinical trial material.

· Other projects and infrastructure costs. In the six months ended June 30, 2020, expenses were slightly higher compared to the previous year and related to our earlier stage programs and discovery/early stage development activities and infrastructure costs.

General and administrative expenses

General and administrative expenses for the six months ended June 30, 2020 were €6.1 million, compared with €4.8 million for the six months ended June 30, 2019. The increase is mainly due to higher personnel expenses, higher compliance costs with the Sarbanes-Oxley Act of 2002, and legal, consulting and audit costs.

Finance income / (costs)-net

Finance income for the six months ended June 30, 2020 was €0.7 million, compared with finance income of €0.2 million for the six months ended June 30, 2019. Finance income in the six months ended June 30, 2020 is primarily related to foreign exchange gains.

Liquidity and Capital Resources

Since inception, we have incurred significant operating losses. To date, we have not generated any product sale revenue. We have financed our operations primarily through our public offerings of our common shares, private placements of equity securities and loans, grants and payments from collaboration partners.

Cash flows

The table below summarizes our consolidated statement of cash flows for the six months ended June 30, 2020 and 2019:

	Six months ended June 30,
	2020	2019
	(unaudited)
	(in € thousand)

Net cash used in operating activities	(31,538)	(18,941)
Net cash used in investing activities	811	(10,411)
Net cash provided by financing activities	19,646	(1,280)
Exchange rate related changes of cash and cash equivalents	431	(210)
Net changes to cash and cash equivalents	(11,081)	(30,632)
Cash and cash equivalents at the beginning of the period	95,234	94,829
Cash and cash equivalents at the end of the period	84,584	63,987

Net cash used in operating activities of €31.5 million in the six months ended June 30, 2020 is higher than net cash used in operating activities in the six months ended June 30, 2019 (€18.9 million) primarily due to higher operating expenses and lower cash inflows from revenues. The investing activities in the six months ended June 30, 2020 and 2019 primarily relate to investments in and proceeds from the sale or maturity of financial assets. Net cash provided by financing activities in the six months ended June 30, 2020 relate primarily to the issuance of shares in connection with our at-the-market sales agreement. Net cash used in financing activities in the six months ended June 30, 2019 relate primarily to the repayment of borrowings.

Cash and Funding Sources

Our cash and cash equivalents and financial assets as of June 30, 2020 were €92.6 million, compared with €104.1 million as of December 31, 2019. Funding sources generally comprise proceeds from the issuance of equity instruments, payments from collaboration agreements, loans and government grants.

Funding Requirements

We expect that we will require additional funding to complete the development of our product candidates and to continue to advance the development of our other product candidates. If we receive regulatory approval for AFM13, AFM24 or other earlier programs, and if we choose not to grant any licenses to partners, we expect to incur significant commercialization expenses related to product manufacturing, sales, marketing and distribution, depending on where we choose to commercialize. We also continue to incur substantial costs associated with operating as a public company. Additional funds may not be available on a timely basis, on favorable terms, or at all, and such funds, if raised, may not be sufficient to enable us to continue to implement our long-term business strategy. If we are not able to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts.

Based on our current operating and budget assumptions, we believe that our existing liquidity, will enable us to fund our operating expenses and capital expenditure requirements into the first half of 2022. We have based this estimate on assumptions that may prove to be incorrect, and we could use our capital resources sooner than we currently expect. Our future funding requirements will depend on many factors, including but not limited to:

· the scope, rate of progress, results and cost of our clinical trials, nonclinical testing, and other related activities;

· the cost of manufacturing clinical supplies, and establishing commercial supplies, of our product candidates and any products that we may develop;

· the number and characteristics of product candidates that we pursue;

· the cost, timing, and outcomes of regulatory approvals;

· the cost and timing of establishing sales, marketing, and distribution capabilities; and

· the terms and timing of any collaboration, licensing, and other arrangements that we may establish, including any required milestone and royalty payments thereunder.

To address our financing needs, we may raise additional capital through the sale of equity or convertible debt securities. In such an event, the ownership interest of our shareholders will be diluted, and the terms of any such securities may include liquidation or other preferences that adversely affect the rights of holders of our common shares.

For more information as to the risks associated with our future funding needs, see “Risk Factors” in the Annual Report.

Contractual Obligations and Commitments

As of the date of this discussion and analysis there are no material changes to our contractual obligations from those reported in “Item 5. Operating and Financial Review and Prospects—F. Tabular disclosure of contractual obligations” in the Annual Report.

Off-balance Sheet Arrangements

As of the date of this discussion and analysis, we do not have any, and during the periods presented we did not have any, off-balance sheet arrangements other than operating leases as described under “Item 5. Operating and Financial Review and Prospects—F. Tabular disclosure of contractual obligations” in the Annual Report.

Quantitative and Qualitative Disclosures About Market Risk

During the six months ended June 30, 2020 there were no significant changes to our quantitative and qualitative disclosures about market risk from those reported in “Item 11. Quantitative and Qualitative Disclosures About Risk” in the Annual Report.

Critical Judgments and Accounting Estimates

There have been no material changes to the significant accounting policies and estimates described in “Item 5. Operating and Financial Review and Prospects—A. Operating Results Overview—Critical Judgments and Accounting Estimates” in the Annual Report.

Recent Accounting Pronouncements

We refer to note 2 of the notes to the unaudited interim condensed consolidated financial statements for the three and six month periods ended June 30, 2020 and 2019 with regard to the impact of recent accounting pronouncements.

Cautionary Statement Regarding Forward Looking Statements

Forward-looking statements appear in a number of places in this discussion and analysis and include, but are not limited to, statements regarding our intent, belief or current expectations. Many of the forward-looking statements contained in this discussion and analysis can be identified by the use of forward-looking words such as “anticipate,” “believe,” “could,” “expect,” “should,” “plan,” “intend,”

“estimate” and “potential,” among others. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to of various factors, including, but not limited to, those identified under the section entitled “Risk Factors” in the Annual Report. These risks and uncertainties include factors relating to:

· our operation as a development stage company with a history of operating losses; as of June 30, 2020, our accumulated deficit was €255.0 million;

· the chance our clinical trials may be delayed or put on clinical hold, for example, due to slower than expected enrollment or regulatory actions, or not be successful and clinical results may not reflect results seen in previously conducted preclinical studies and clinical trials, or expectations based on these preclinical studies and clinical trials;

· our reliance on contract manufacturers and contract research organizations over which we have limited control;

· our lack of adequate funding to complete development of our product candidates and the risk we may be unable to access additional capital on reasonable terms or at all to complete development and begin commercialization of our product candidates;

· our dependence on the success of AFM24 and AFM13 (which are still in clinical development) and certain of our other product candidates, each of which may eventually prove to be unsuccessful or commercially not exploitable;

· uncertainty surrounding whether any of our product candidates will gain regulatory approval, which is necessary before they can be commercialized;

· the outcome of any, or any discussions we may enter regarding, acquisitions, dispositions, partnerships, license transactions or changes to our capital structure, including our receipt of any milestone payments or royalties or any future securities offerings;

· the chance that we may become exposed to costly and damaging liability claims resulting from the testing of our product candidates in the clinic or in the commercial stage;

· if our product candidates obtain regulatory approval, our being subject to expensive ongoing obligations and continued regulatory overview;

· enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval and commercialization;

· future legislation may materially impact our ability to realize revenue from any approved and commercialized products;

· the chance that our products may not gain market acceptance, in which case we may not be able to generate product revenues;

· our reliance on our current strategic relationships with LLS, Merck, The MD Anderson Cancer Center, Genentech, Amphivena and the potential failure to enter into new strategic relationships;

· our reliance on third parties to conduct our nonclinical and clinical trials and on third-party single-source suppliers to supply or produce our product candidates;

· our ability to scale-up manufacturing processes of our product candidates and reduce the cost of manufacturing our product candidates in advance of any commercialization;

· our future growth and ability to compete, which depends on retaining our key personnel and recruiting additional qualified personnel;

· the length and severity of the COVID-19 outbreak and its impact on our business, including our supply chain, clinical trials and operations; and

· other risk factors discussed under “Item 3. Key Information—D. Risk Factors” in the Annual Report.

Our actual results or performance could differ materially from those expressed in, or implied by, any forward-looking statements relating to those matters. Accordingly, no assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what impact they will have on our results of operations, cash flows or financial condition.

Additionally, some of the risks and uncertainties identified above may be amplified by the recent COVID-19 outbreak. It is not possible to predict or identify all such risks. There may be additional risks that we consider immaterial or which are unknown. Except as required by law, we are under no obligation, and expressly disclaim any obligation, to update, alter or otherwise revise any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future events or otherwise.

EX-99.3 4 a20-26176_1ex99d3.htm EX-99.3

Exhibit 99.3

PRESS RELEASE

Affimed Reports Second Quarter 2020 Financial Results and

Operational Progress

· Continued progress in the AFM13 pTCL REDIRECT monotherapy study

· AFM24 is recruiting patients in cohort 2 of a Phase 1/2a clinical trial

· Genentech’s RO7297089 is actively recruiting patients into a first-in-human Phase I trial resulting in the achievement of a milestone payment under the terms of the collaboration

· Data on AFM24 and RO7297089 (formerly AFM26) were presented at the virtual AACR II conference in June

· Angus Smith joins the company as Chief Financial Officer

· Dr. Annalisa Jenkins and Harry Welten added to the Supervisory Board

· €92.6 million of cash, cash equivalents and current financial assets as of June 30, 2020, providing anticipated cash runway into the first half of 2022

· Conference call and webcast scheduled for August 11, 2020 at 8:30 am EDT (14:30 CET)

Heidelberg, Germany, August 11, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today reported financial results for the second quarter 2020 and provided an update on clinical and corporate progress.

“Affimed’s first half performance demonstrates the strength of the new management team and our ability to stay focused on executing our business strategy despite the continuing challenge of the COVID-19 environment. Always with the patient in mind, we are committed to advancing our pipeline as well as continuing to deepen our research to unlock the full potential of the innate immune system to fight cancer,” said Dr. Adi Hoess, CEO of Affimed. “We have multiple Innate Cell Engager (ICE®) programs in clinical development, both partnered and wholly-owned, which are the basis for providing a cadence of a continuous data output in 2020 and 2021.”

Development Program Updates

AFM13 (CD30/CD16A)

· Affimed has now successfully activated 54 clinical study sites in 10 countries in the on-going Phase 2 registration-directed study of AFM13 as monotherapy in relapsed or refractory patients with CD30-positive peripheral T-cell lymphoma (pTCL). The study follows a two-stage Simon design with a preplanned interim analysis after 40 patients. At the current recruitment rate the company expects the readout of the interim analysis to happen in mid-2021.

· The investigator-sponsored Phase 1 study with the University of Texas, MD Anderson Cancer Center (MDACC), which investigates the combination of AFM13 with allogeneic NK cells in CD30+ Lymphomas, has completed the required validation work in order to administer a stable complex of AFM13 pre-mixed with cord blood-derived allogeneic NK cells. MDACC has recently posted this study as enrolling on its website and it is expected to recruit patients as soon as the COVID-19 conditions in Texas permit.

AFM24 (EGFR/CD16A)

· AFM24-101, a first-in-human Phase 1/2a clinical trial of AFM24, the EGFR/CD16A targeted innate cell engager for relapsed/ refractory patients with advanced EGFR-expressing solid tumors continues to recruit according to plan in cohort 2.

· AFM24-101 is an open-label, non-randomized, multi-center, multiple ascending dose escalation/expansion study to evaluate AFM24 as monotherapy in adult patients with advanced solid malignancies known to be EGFR-positive.

· No dose limiting toxicity was observed in dose cohort 1.

· A preclinical poster presentation was shown at the virtual AACR II conference in June on AFM24, demonstrating that it is differentiated from all other EGFR targeting entities: (i) it appears safe - no skin toxicity or other dose limiting toxicities (DLTs) in cynomolgus monkeys, (ii) it addresses a broad patient population – AFM24 targets EGFR independent of its mutational status, and (iii) in contrast to monoclonal antibodies, AFM24 strongly activates NK cells and macrophages.

Genentech Collaboration Update

· The Genentech-partnered, novel BCMA-targeted innate cell engager for the treatment of multiple myeloma has now entered a first-in-human Phase I, open-label, multicenter, global dose-escalation study designed to evaluate the safety, tolerability, and pharmacokinetics of RO7297089. The milestone was achieved in the third quarter and triggers a payment in an undisclosed amount to Affimed, which is expected to be recognized in the Company’s third quarter 2020 financial statements.

· At the June virtual AACR II conference, a preclinical poster presentation on RO7297089 showed potent cell killing in tumor cell lines employing NK cells as effector cells with

minimal increase in cytokines. A 4-week safety study in cynomolgus monkeys showed a favorable safety profile with no cytokine release or adverse findings at the 15 and 50 mg/kg tested dose levels. Furthermore, time- and dose-dependent reductions in serum IgG levels and plasma cell markers were observed suggesting selective killing of BCMA positive cells by engaging CD16a positive immune cells.

Preclinical Pipeline Update

· Progress continues on AFM28 and AFM32 towards late stage preclinical development.

Management Appointments

· Angus Smith joined the company as Chief Financial Officer on July 13. Mr. Smith brings broad biopharmaceutical experience to the company including financial strategy and planning, capital markets, business development and operations. Mr. Smith’s appointment completes the planned additions to the management team which now includes Dr. Andreas Harstrick, Chief Medical Officer and Dr. Arndt Schottelius, Chief Scientific Officer.

Additions to the Supervisory Board

· Dr. Annalisa Jenkins and Harry Welten were appointed to the Supervisory Board during the recent Annual General Meeting of Shareholders. Dr. Jenkins brings a wealth of expertise in advancing clinical programs through development and regulatory approval. Mr. Welten is an accomplished financial executive who is well suited to help drive value-creating strategies for the company. These additions to the Supervisory Board are expected to further strengthen the company’s industry know-how, experience and diversity.

Second Quarter 2020 Financial Highlights

(Figures for the second quarter ended June 30, 2020 and 2019 are unaudited.)

As of June 30, 2020, cash, cash equivalents and current financial assets totaled €92.6 million compared to €104.1 million on December 31, 2019. During the quarter, the company received net proceeds of approximately €20.8 million under its at-the-market (“ATM”) program.

Based on its current operating plan and assumptions, Affimed anticipates that its cash, cash equivalents and current financial assets will support operations into the first half of 2022.

Net cash used in operating activities for the quarter ended June 30, 2020 was €15.0 million compared to €5.6 million in the second quarter of 2019. The second quarter 2019 net cash used in operating activities included a milestone payment to the company from the Genentech collaboration.

Total revenue for the second quarter of 2020 was €2.9 million compared with €4.0 million in the second quarter of 2019. Revenue in 2020 and 2019 predominantly relate to the Genentech collaboration (2020: €2.7 million, 2019: €3.7 million). Revenue from the Genentech collaboration in the second quarter 2020 was comprised of revenue recognized for collaborative research services performed during the quarter.

R&D expenses for the second quarter of 2020 were €11.7 million compared to €11.5 million in the second quarter of 2019. Expenses in 2020 relate predominantly to our AFM13 and AFM24 clinical programs as well as to our early stage development and discovery activities.

G&A expenses for the second quarter of 2020 were €2.6 million compared to €2.3 million in the second quarter of 2019. The increase is primarily related to higher Sarbanes-Oxley compliance costs, as well as an increase in legal, consulting and audit costs.

Net loss for the second quarter of 2020 was €12.2 million or €0.16 per common share. For the second quarter of 2019, the company’s net loss was €10.3 million or €0.17 per common share.

Weighted number of common shares outstanding for the quarter ended June 30, 2020 were 79.2 million.

Affimed encourages shareholders to also review its 6-K filing for the quarter ended June 30, 2020, as filed with the United States Securities and Exchange Commission.

Note on International Financial Reporting Standards (IFRS)

Affimed prepares and reports consolidated financial statements and financial information in accordance with IFRS as issued by the International Accounting Standards Board. None of the financial statements were prepared in accordance with Generally Accepted Accounting Principles in the United States. Affimed maintains its books and records in Euro.

Conference Call and Webcast Information

Affimed will host a conference call and webcast today, Tuesday, August 11, 2020 at 8:30 a.m. EDT to discuss second quarter 2020 financial results and recent corporate developments. The conference call will be available via phone and webcast.

To access the call, please dial +1 (646) 741-3167 for U.S. callers, or +44 (0) 2071 928338 for international callers, and reference passcode 8855368 approximately 15 minutes prior to the call.

A live audio webcast of the conference call will be available in the “Webcasts” section on the “Investors” page of the Affimed website at https://www.affimed.com/investors/webcasts_cp/. A replay of the webcast will be accessible at the same link for 30 days following the call.

About Affimed N.V.

Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer. Affimed’s fit-for-purpose ROCK® platform allows innate cell engagers to be designed for specific patient populations. The company is developing single and combination therapies to treat hematologic and solid tumors. The company is currently enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T cell lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. For more information, please visit www.affimed.com.

Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions. Forward-looking statements appear in a number of places throughout this release and include statements regarding our intentions, beliefs, projections, outlook, analyses and current expectations concerning, among other things, the potential of AFM24, the value of our ROCK® platform, our ongoing and planned preclinical development and clinical trials, our collaborations and development of our products in combination with other therapies, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates, our intellectual property position, our collaboration activities, our ability to develop commercial functions, clinical trial data, our results of operations, cash needs, financial condition, liquidity, prospects, future transactions, growth and strategies, the industry in which we operate, the trends that may affect the industry or us, impacts of the COVID-19 pandemic, the benefits to Affimed of orphan drug designation and the risks, uncertainties and other factors described under the heading “Risk Factors” in Affimed’s filings with the SEC. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.

Investor & Media Contact:

Alex Fudukidis

Head of Investor Relations

E-Mail: a.fudukidis@affimed.com

Tel.: (917) 436-8102

Affimed N.V.

Unaudited consolidated statements of comprehensive income / (loss) (in € thousand)

	For the three months ended June 30		For the six months ended June 30
	2020	2019	2020	2019

Revenue	2,934	4,008	8,069	15,361

Other income – net	85	197	28	283
Research and development expenses	(11,697)	(11,545)	(23,146)	(19,532)
General and administrative expenses	(2,606)	(2,342)	(6,131)	(4,776)

Operating income / (loss)	(11,284)	(9,682)	(21,180)	(8,664)

Finance income / (costs) – net	(954)	(654)	653	180

Income / (loss) before tax	(12,238)	(10,336)	(20,527)	(8,484)

Income taxes	0	(4)	0	(4)

Income / (loss) for the period	(12,238)	(10,340)	(20,527)	(8,488)

Other comprehensive income / (loss) Items that will not be reclassified to profit or loss Equity investments at fair value OCI – net change in fair value	(71)	(49)	10	24

Other comprehensive income / (loss)	(71)	(49)	10	24

Total comprehensive income / (loss)	(12,309)	(10,389)	(20,517)	(8,464)

Earnings / (loss) per share in € per share	(0.16)	(0.17)	(0.26)	(0.14)

(undiluted = diluted)
Weighted number of common shares outstanding	79,189,686	62,439,363	77,719,793	62,434,734

Affimed N.V.

Consolidated statements of financial position (in € thousand)

	June 30, 2020	December 31, 2019
	(unaudited)
ASSETS
Non-current assets
Intangible assets	103	137
Leasehold improvements and equipment	2,237	2,291
Long term financial assets	3,203	3,193
Right-of-use assets	536	824
	6,079	6,445
Current assets
Cash and cash equivalents	84,584	95,234
Financial assets	8,037	8,902
Trade and other receivables	2,027	1,482
Inventories	421	296
	95,069	105,914

TOTAL ASSETS	101,148	112,359

EQUITY AND LIABILITIES
Equity
Issued capital	845	762
Capital reserves	292,720	270,451
Fair value reserves	1,972	1,962
Accumulated deficit	(255,035)	(234,508)
Total equity	40,502	38,667

Non-current liabilities
Borrowings	231	278
Contract liabilities	27,829	37,961
Lease liabilities	95	272
Total non-current liabilities	28,155	38,511

Current liabilities
Trade and other payables	6,606	10,674
Provisions	484	517
Borrowings	1,039	2,105
Lease liabilities	451	532
Contract liabilities	23,911	21,353
Total current liabilities	32,491	35,181

TOTAL EQUITY AND LIABILITIES	101,148	112,359

Affimed N.V.

Unaudited consolidated statements of cash flows (in € thousand)

	For the six months ended June 30,
	2020	2019
Cash flow from operating activities
Income / (loss) for the period	(20,527)	(8,488)
Adjustments for the period:
- Income taxes	0	4
- Depreciation and amortisation	551	423
- Net gain from disposal of leasehold improvements and equipment	0	(9)
- Share based payments	1,410	1,167
- Finance income / costs – net	(653)	(180)
	(19,219)	(7,083)
Change in trade and other receivables	(649)	228
Change in inventories	(125)	(70)
Change in other assets	0	(2,586)
Change in trade, other payables, provisions and contract liabilities	(11,757)	(9,484)
Cash used in operating activities	(31,750)	(18,995)
Interest received	276	188
Paid interest	(64)	(134)
Net cash used in operating activities	(31,538)	(18,941)

Cash flow from investing activities
Purchase of intangible assets	(2)	(142)
Purchase of leasehold improvements and equipment	(174)	(755)
Cash paid for investments in financial assets	(8,101)	(35,262)
Cash received from maturity of financial assets	9,088	25,748
Net cash used for investing activities	811	(10,411)

Cash flow from financing activities
Proceeds from issue of common shares	21,785	13
Transaction costs related to issue of common shares	(754)	0
Proceeds from borrowings	0	562
Repayment of lease liabilities	(257)	(206)
Repayment of borrowings	(1,128)	(1,649)
Cash flow from financing activities	19,646	(1,280)

Exchange-rate related changes of cash and cash equivalents	431	(210)
Net changes to cash and cash equivalents	(11,081)	(30,632)
Cash and cash equivalents at the beginning of the period	95,234	94,829
Cash and cash equivalents at the end of the period	84,584	63,987

Affimed N.V.

Unaudited consolidated statements of changes in equity (in € thousand)

	Issued capital	Capital reserves	Fair Value reserves	Accumulated deficit	Total equity

Balance as of January 1, 2019	624	239,055	2,594	(202,144)	40,129

Exercise of share based payment awards		13			13
Equity-settled share based payment awards		1,167			1,167
Loss for the period				(8,488)	(8,488)
Other comprehensive income			24		24

Balance as of June 30, 2019	624	240,235	2,618	(210,632)	32,845



Balance as of January 1, 2020	762	270,451	1,962	(234,508)	38,667


Issue of common shares	83	20,859			20,942
Equity-settled share based payment awards		1,410			1,410
Loss for the period				(20,527)	(20,527)
Other comprehensive income			10		10

Balance as of June 30, 2020	845	292,720	1,972	(255,035)	40,502

EX-101.INS 5 afmd-20200630.xml EX-101.INS 0001608390 afmd:TrancheIMember 2018-04-01 2018-04-30 0001608390 afmd:TrancheIiMember 2018-04-01 2018-04-30 0001608390 afmd:TrancheIiiMember 2018-04-01 2018-04-30 0001608390 afmd:SeniorSecuredTermLoanFacilityMember 2017-09-30 0001608390 afmd:GenentechIncMember 2019-01-01 2019-12-31 0001608390 afmd:GenentechIncMember 2020-04-01 2020-06-30 0001608390 afmd:AbCheckMember 2020-04-01 2020-06-30 0001608390 afmd:LeukemiaAndLymphomaSocietyMember 2020-01-01 2020-06-30 0001608390 afmd:GenentechIncMember 2020-01-01 2020-06-30 0001608390 afmd:AbCheckMember 2020-01-01 2020-06-30 0001608390 afmd:GenentechIncMember 2019-04-01 2019-06-30 0001608390 afmd:AbCheckMember 2019-04-01 2019-06-30 0001608390 afmd:LeukemiaAndLymphomaSocietyMember 2019-01-01 2019-06-30 0001608390 afmd:GenentechIncMember 2019-01-01 2019-06-30 0001608390 afmd:AbCheckMember 2019-01-01 2019-06-30 0001608390 srt:EuropeMember 2020-04-01 2020-06-30 0001608390 ifrs-full:GoodsOrServicesTransferredOverTimeMember 2020-04-01 2020-06-30 0001608390 ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember 2020-04-01 2020-06-30 0001608390 country:US 2020-04-01 2020-06-30 0001608390 country:DE 2020-04-01 2020-06-30 0001608390 afmd:ServicesMember 2020-04-01 2020-06-30 0001608390 afmd:CollaborationServiceMember 2020-04-01 2020-06-30 0001608390 srt:EuropeMember 2020-01-01 2020-06-30 0001608390 ifrs-full:GoodsOrServicesTransferredOverTimeMember 2020-01-01 2020-06-30 0001608390 ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember 2020-01-01 2020-06-30 0001608390 country:US 2020-01-01 2020-06-30 0001608390 country:DE 2020-01-01 2020-06-30 0001608390 afmd:ServicesMember 2020-01-01 2020-06-30 0001608390 afmd:CollaborationServiceMember 2020-01-01 2020-06-30 0001608390 srt:EuropeMember 2019-04-01 2019-06-30 0001608390 ifrs-full:GoodsOrServicesTransferredOverTimeMember 2019-04-01 2019-06-30 0001608390 ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember 2019-04-01 2019-06-30 0001608390 country:US 2019-04-01 2019-06-30 0001608390 country:DE 2019-04-01 2019-06-30 0001608390 afmd:ServicesMember 2019-04-01 2019-06-30 0001608390 afmd:CollaborationServiceMember 2019-04-01 2019-06-30 0001608390 srt:EuropeMember 2019-01-01 2019-06-30 0001608390 ifrs-full:GoodsOrServicesTransferredOverTimeMember 2019-01-01 2019-06-30 0001608390 ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember 2019-01-01 2019-06-30 0001608390 country:US 2019-01-01 2019-06-30 0001608390 country:DE 2019-01-01 2019-06-30 0001608390 afmd:ServicesMember 2019-01-01 2019-06-30 0001608390 afmd:CollaborationServiceMember 2019-01-01 2019-06-30 0001608390 afmd:LoanAgreementWithUniCreditLeasingCZMember 2020-04-01 2020-06-30 0001608390 ifrs-full:RevaluationSurplusMember 2020-01-02 2020-06-30 0001608390 ifrs-full:RevaluationSurplusMember 2019-01-02 2019-06-30 0001608390 afmd:SharesIssuedUnderAtMarketSalesAgreementMember 2020-06-30 0001608390 2020-05-31 0001608390 2018-04-30 0001608390 afmd:Esop2014Member 2020-06-30 0001608390 afmd:Esop2014Member 2019-12-31 0001608390 afmd:Esop2014Member 2019-01-01 2019-12-31 0001608390 ifrs-full:IssuedCapitalMember 2020-01-02 2020-06-30 0001608390 ifrs-full:CapitalReserveMember 2020-01-02 2020-06-30 0001608390 ifrs-full:CapitalReserveMember 2019-01-02 2019-06-30 0001608390 afmd:SiliconValleyBankLoanMember 2020-06-30 0001608390 afmd:SiliconValleyBankLoanMember 2019-12-31 0001608390 afmd:OtherFinanceIncomeFinanceCostsMember 2020-04-01 2020-06-30 0001608390 afmd:InterestSVBLoanAgreementMember 2020-04-01 2020-06-30 0001608390 afmd:GainFromModificationOfSvbLoanAgreementMember 2020-04-01 2020-06-30 0001608390 afmd:ForeignExchangeDifferencesMember 2020-04-01 2020-06-30 0001608390 afmd:FinanceCostLeaseLiabilityMember 2020-04-01 2020-06-30 0001608390 afmd:OtherFinanceIncomeFinanceCostsMember 2020-01-01 2020-06-30 0001608390 afmd:LoanAgreementWithUniCreditLeasingCZMember 2020-01-01 2020-06-30 0001608390 afmd:InterestSVBLoanAgreementMember 2020-01-01 2020-06-30 0001608390 afmd:GainFromModificationOfSvbLoanAgreementMember 2020-01-01 2020-06-30 0001608390 afmd:ForeignExchangeDifferencesMember 2020-01-01 2020-06-30 0001608390 afmd:FinanceCostLeaseLiabilityMember 2020-01-01 2020-06-30 0001608390 afmd:OtherFinanceIncomeFinanceCostsMember 2019-04-01 2019-06-30 0001608390 afmd:InterestSVBLoanAgreementMember 2019-04-01 2019-06-30 0001608390 afmd:GainFromModificationOfSvbLoanAgreementMember 2019-04-01 2019-06-30 0001608390 afmd:ForeignExchangeDifferencesMember 2019-04-01 2019-06-30 0001608390 afmd:FinanceCostLeaseLiabilityMember 2019-04-01 2019-06-30 0001608390 afmd:OtherFinanceIncomeFinanceCostsMember 2019-01-01 2019-06-30 0001608390 afmd:InterestSVBLoanAgreementMember 2019-01-01 2019-06-30 0001608390 afmd:GainFromModificationOfSvbLoanAgreementMember 2019-01-01 2019-06-30 0001608390 afmd:ForeignExchangeDifferencesMember 2019-01-01 2019-06-30 0001608390 afmd:FinanceCostLeaseLiabilityMember 2019-01-01 2019-06-30 0001608390 ifrs-full:PreferenceSharesMember 2020-06-30 0001608390 afmd:ResearchAndDevelopmentMember 2020-04-01 2020-06-30 0001608390 afmd:GeneralAndAdministrativeMember 2020-04-01 2020-06-30 0001608390 afmd:ResearchAndDevelopmentMember 2020-01-01 2020-06-30 0001608390 afmd:GeneralAndAdministrativeMember 2020-01-01 2020-06-30 0001608390 afmd:ResearchAndDevelopmentMember 2019-04-01 2019-06-30 0001608390 afmd:GeneralAndAdministrativeMember 2019-04-01 2019-06-30 0001608390 afmd:ResearchAndDevelopmentMember 2019-01-01 2019-06-30 0001608390 afmd:GeneralAndAdministrativeMember 2019-01-01 2019-06-30 0001608390 ifrs-full:TopOfRangeMember afmd:Esop2014Member 2020-06-30 0001608390 ifrs-full:BottomOfRangeMember afmd:Esop2014Member 2020-06-30 0001608390 ifrs-full:RevaluationSurplusMember 2020-06-30 0001608390 ifrs-full:RetainedEarningsMember 2020-06-30 0001608390 ifrs-full:CapitalReserveMember 2020-06-30 0001608390 ifrs-full:RevaluationSurplusMember 2020-01-01 0001608390 ifrs-full:RetainedEarningsMember 2020-01-01 0001608390 ifrs-full:IssuedCapitalMember 2020-01-01 0001608390 ifrs-full:CapitalReserveMember 2020-01-01 0001608390 2020-01-01 0001608390 ifrs-full:RevaluationSurplusMember 2019-06-30 0001608390 ifrs-full:RetainedEarningsMember 2019-06-30 0001608390 ifrs-full:IssuedCapitalMember 2019-06-30 0001608390 ifrs-full:CapitalReserveMember 2019-06-30 0001608390 ifrs-full:RevaluationSurplusMember 2019-01-01 0001608390 ifrs-full:RetainedEarningsMember 2019-01-01 0001608390 ifrs-full:IssuedCapitalMember 2019-01-01 0001608390 ifrs-full:CapitalReserveMember 2019-01-01 0001608390 2019-01-01 0001608390 afmd:AnnualImprovements20182020Member 2020-01-01 2020-06-30 0001608390 afmd:AmendmentToIfrs16LeasesCovid19RelatedRentConcessionsMember 2020-01-01 2020-06-30 0001608390 afmd:AmendmentsToReferencesToConceptionalFrameworkMember 2020-01-01 2020-06-30 0001608390 afmd:AmendmentsToIfrs9Ias39AndIfrs7InterestRateBenchmarkReformMember 2020-01-01 2020-06-30 0001608390 afmd:AmendmentsToIfrs3BusinessCombinationsMember 2020-01-01 2020-06-30 0001608390 afmd:AmendmentsToIfrs3BusinessCombinationMember 2020-01-01 2020-06-30 0001608390 afmd:AmendmentsToIas1PresentationOfFinancialStatementsClassificationOfLiabilitiesAsCurrentOrNonCurrentMember 2020-01-01 2020-06-30 0001608390 afmd:AmendmentsToIas1AndIas8DefinitionOfMaterialMember 2020-01-01 2020-06-30 0001608390 afmd:AmendmentsToIas16PropertyPlantAndEquipmentMember 2020-01-01 2020-06-30 0001608390 afmd:AmendmentsToAs37ProvisionsContingentLiabilitiesAndContingentAssetsMember 2020-01-01 2020-06-30 0001608390 2019-06-30 0001608390 2018-12-31 0001608390 afmd:SiliconValleyBankLoanMember afmd:OneMonthEURIBORMember 2016-11-30 0001608390 afmd:LoanAgreementWithUniCreditLeasingCZMember 2019-12-31 0001608390 afmd:LoanAgreementWithUniCreditLeasingCZMember 2019-04-30 0001608390 afmd:SeniorSecuredTermLoanFacilityTrancheTwoMember 2017-05-31 0001608390 afmd:SeniorSecuredTermLoanFacilityTrancheOneMember 2016-12-31 0001608390 afmd:WolfgangFischerMember 2020-06-30 0001608390 afmd:UlrichGrauMember 2020-06-30 0001608390 afmd:ThomasHechtMember 2020-06-30 0001608390 afmd:MathieuSimonMember 2020-06-30 0001608390 afmd:FerdinandVerdonckMember 2020-06-30 0001608390 afmd:BernhardEhmerMember 2020-06-30 0001608390 afmd:BemdtModigMember 2020-06-30 0001608390 afmd:AdiHoessMember 2020-06-30 0001608390 afmd:WolfgangFischerMember 2018-12-31 0001608390 afmd:UlrichGrauMember 2018-12-31 0001608390 afmd:ThomasHechtMember 2018-12-31 0001608390 afmd:MathieuSimonMember 2018-12-31 0001608390 afmd:FerdinandVerdonckMember 2018-12-31 0001608390 afmd:BernhardEhmerMember 2018-12-31 0001608390 afmd:BemdtModigMember 2018-12-31 0001608390 afmd:AdiHoessMember 2018-12-31 0001608390 2020-06-30 0001608390 2019-12-31 0001608390 afmd:GenentechIncMember 2020-06-30 0001608390 2020-04-01 2020-06-30 0001608390 2019-04-01 2019-06-30 0001608390 2019-01-01 2019-06-30 0001608390 2018-04-01 2018-04-30 0001608390 afmd:Esop2014Member 2020-04-01 2020-06-30 0001608390 2019-01-01 2019-12-31 0001608390 afmd:SupervisoryBoardDirectorsMember 2020-04-01 2020-06-30 0001608390 afmd:KeyManagementPersonnelMember 2020-04-01 2020-06-30 0001608390 afmd:SupervisoryBoardDirectorsMember 2020-01-01 2020-06-30 0001608390 afmd:KeyManagementPersonnelMember 2020-01-01 2020-06-30 0001608390 afmd:SupervisoryBoardDirectorsMember 2019-04-01 2019-06-30 0001608390 afmd:KeyManagementPersonnelMember 2019-04-01 2019-06-30 0001608390 afmd:SupervisoryBoardDirectorsMember 2019-01-01 2019-06-30 0001608390 afmd:KeyManagementPersonnelMember 2019-01-01 2019-06-30 0001608390 ifrs-full:RetainedEarningsMember 2020-01-02 2020-06-30 0001608390 2020-01-02 2020-06-30 0001608390 ifrs-full:RetainedEarningsMember 2019-01-02 2019-06-30 0001608390 2019-01-02 2019-06-30 0001608390 afmd:SeniorSecuredTermLoanFacilityMember 2016-11-30 0001608390 afmd:SiliconValleyBankLoanMember 2018-12-31 0001608390 afmd:SiliconValleyBankLoanMember 2017-12-31 0001608390 afmd:SiliconValleyBankLoanMember ifrs-full:TopOfRangeMember 2016-11-30 2016-11-30 0001608390 afmd:SiliconValleyBankLoanMember ifrs-full:BottomOfRangeMember 2016-11-30 2016-11-30 0001608390 afmd:Esop2014Member 2020-01-01 2020-06-30 0001608390 afmd:SeniorSecuredTermLoanFacilityMember 2016-11-30 2016-11-30 0001608390 afmd:LoanAgreementWithUniCreditLeasingCZMember 2020-06-30 0001608390 afmd:SiliconValleyBankLoanMember 2016-11-30 2016-11-30 0001608390 afmd:GenentechIncMember 2018-10-01 2018-10-31 0001608390 2020-01-01 2020-06-30 0001608390 ifrs-full:IssuedCapitalMember 2020-06-30 afmd:EquityInstruments afmd:Y afmd:D iso4217:EUR xbrli:shares xbrli:shares iso4217:USD xbrli:shares afmd:tranche xbrli:pure iso4217:USD iso4217:EUR 21000000 <div> <div> 2.     Basis of preparation and changes to Group’s accounting policies Statement of compliance The interim financial statements for the three and six months ended June 30, 2020 and 2019 have been prepared in accordance with IAS 34 Interim Financial Reporting. The interim financial statements do not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with Affimed N.V.’s annual consolidated financial statements as of December 31, 2019. The interim financial statements were authorized for issuance by the management board on August 11, 2020. Critical judgments and accounting estimates The preparation of the interim financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. In preparing these interim financial statements, the critical judgments made by management in applying the Company’s accounting policies were the same as those that applied to the consolidated financial statements as of and for the year ended December 31, 2019. Functional and presentation currency These interim financial statements are presented in Euro, which is the Company’s functional currency. All financial information presented in Euro has been rounded to the nearest thousand (abbreviated €) or million (abbreviated € million). Significant accounting policies The accounting policies applied by the Company in these interim financial statements are the same as those applied by the Company in its consolidated financial statements as of and for the year ended December 31, 2019 with the exception of new amendments to standards and new or amended interpretations applied for the first time as described below. New standards and interpretations applied for the first time The following amendments to standards and new or amended interpretations are effective for annual periods beginning on or after January 1, 2020, and have been applied  in preparing these financial statements: <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;font-family:Arial,Helvetica,sans-serif;"> <tr> <td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:70.56%;padding:0pt;"> Standard/interpretation </td> <td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:29.44%;padding:0pt;"> Effective Date </td> </tr> <tr> <td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:70.56%;padding:0pt;">   </td> <td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:29.44%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:70.56%;padding:0pt;"> Amendments to References to the Conceptional Framework </td> <td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:29.44%;padding:0pt;"> January 1, 2020 </td> </tr> <tr> <td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:70.56%;padding:0pt;"> Amendments to IAS 1 and IAS 8: Definition of Material </td> <td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:29.44%;padding:0pt;"> January 1, 2020 </td> </tr> <tr> <td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:70.56%;padding:0pt;"> Amendments to IFRS 9, IAS 39 and IFRS 7: Interest Rate Benchmark Reform </td> <td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:29.44%;padding:0pt;"> January 1, 2020 </td> </tr> <tr> <td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:70.56%;padding:0pt;"> Amendments to IFRS 3 Business Combination </td> <td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:29.44%;padding:0pt;"> January 1, 2020 </td> </tr> <tr> <td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:70.56%;padding:0pt;"> Amendment to IFRS 16 Leases Covid 19-Related Rent Concessions </td> <td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:29.44%;padding:0pt;"> June 1, 2020 </td> </tr> <tr> <td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:70.56%;padding:0pt;">   </td> <td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:29.44%;padding:0pt;">   </td> </tr> </table></div>   None of the amendments to standards and new or amended interpretations had a material effect on the interim financial statements.   Fair Value Measurement All assets and liabilities for which fair value is recognized in the interim financial statements are classified in accordance with the following fair value hierarchy, based on the lowest level input parameter that is significant on the whole for fair value measurement: <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"></td><td valign="top" align="left" style="width: 14.00pt;"> · </td><td style="width:14pt;"></td><td align="left" valign="top"> Level 1 – Prices for identical assets or liabilities quoted in active markets (non-adjusted)</td></tr></table></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"></td><td valign="top" align="left" style="width: 14.00pt;"> · </td><td style="width:14pt;"></td><td align="left" valign="top"> Level 2 – Measurement procedures, in which the lowest level input parameter significant on the whole for fair value measurement is directly or indirectly observable for on the market</td></tr></table></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"></td><td valign="top" align="left" style="width: 14.00pt;"> · </td><td style="width:14pt;"></td><td align="left" valign="top"> Level 3 – Measurement procedures, in which the lowest level input parameter significant on the whole for fair value measurement is not directly or indirectly observable for on the market</td></tr></table></div> The carrying amount of all trade and other receivables, certificates of deposit, cash and cash equivalents and trade and other payables is a reasonable approximation of the fair value and, therefore, information about the fair values of those financial instruments has not been disclosed. The measurement of the fair value of the shares held by the group and note disclosure for the fair value of a loan (financial liability) is based on level 2 measurement procedures (see notes 5 and 10). New standards and interpretations not yet adopted The following standards, amendments to standards and interpretations are effective for annual periods beginning after December 31, 2019 and have not been applied in preparing these consolidated financial statements. <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;font-family:Arial,Helvetica,sans-serif;"> <tr> <td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:60.28%;padding:0pt;"> Standard/interpretation </td> <td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:39.72%;padding:0pt;"> Effective Date </td> </tr> <tr> <td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:60.28%;padding:0pt;">   </td> <td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:39.72%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:60.28%;padding:0pt;"> Amendments to IAS 1 Presentation of Financial Statements: </td> <td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:39.72%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:60.28%;padding:0pt;"> Classification of Liabilities as Current or Non-current </td> <td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:39.72%;padding:0pt;"> January 1, 2022 </td> </tr> <tr> <td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:60.28%;padding:0pt;"> Amendments to IFRS 3 Business Combinations </td> <td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:39.72%;padding:0pt;"> January 1, 2022 </td> </tr> <tr> <td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:60.28%;padding:0pt;"> Amendments to IAS 16 Property, Plant and Equipment </td> <td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:39.72%;padding:0pt;"> January 1, 2022 </td> </tr> <tr> <td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:60.28%;padding:0pt;"> Amendments to AS 37 Provisions, Contingent Liabilities and Contingent Assets </td> <td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:39.72%;padding:0pt;"> January 1, 2022 </td> </tr> <tr> <td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:60.28%;padding:0pt;"> Annual Improvements 2018-2020 </td> <td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:39.72%;padding:0pt;"> January 1, 2022 </td> </tr> </table></div>   <div /></div> </div> 4400000 83200000 96000000 0.10 0.055 236000 8000 3 <div> <div> Significant accounting policies The accounting policies applied by the Company in these interim financial statements are the same as those applied by the Company in its consolidated financial statements as of and for the year ended December 31, 2019 with the exception of new amendments to standards and new or amended interpretations applied for the first time as described below. <div /></div> </div> <div> <div> 5.     Long term financial assets The Company holds preferred shares in Amphivena recognized at their fair value of €3.2 million (December 31, 2019: €3.2 million). As of June 30, 2020, the fair value increased by €10 as compared to December 31, 2019 due to exchange rate differences recognized in other comprehensive income for the six months ended June 30, 2020 (2019: increase of €24).  During the three months ended June 30, 2020 and 2019 the fair value decreased by €71 and €49 due to exchange rate differences. <div /></div> </div> P10Y P5Y 0.75 0.80 P10Y P10Y 2.30 2.00 53395 166297 10000000 P2Y P3Y -8488000 -8488000 -20527000 -20527000 81000 8000 1414000 195000 708000 100000 1198000 181000 593000 96000 P3M P3M 197007 197007 3 24000 -49000 10000 -71000 900000 1400000 <div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:33.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:15.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:15.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:13.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:13.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.80%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:15.72%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Three months ended </td> <td valign="bottom" style="width:01.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:15.72%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Three months ended </td> <td valign="bottom" style="width:01.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:13.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Six months ended </td> <td valign="bottom" style="width:01.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:13.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;"> Six months ended </td> </tr> <tr> <td valign="bottom" style="width:33.80%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">      </td> <td valign="bottom" style="width:15.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> June 30, 2020 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">      </td> <td valign="bottom" style="width:15.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> June 30, 2019 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">      </td> <td valign="bottom" style="width:13.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> June 30, 2020 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">      </td> <td valign="bottom" style="width:13.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;"> June 30, 2019 </td> </tr> <tr> <td valign="bottom" style="width:33.80%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Interest SVB Loan Agreement </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:15.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> (59) </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:15.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> (128) </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:13.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> (116) </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:13.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;"> (283) </td> </tr> <tr> <td valign="bottom" style="width:33.80%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Foreign exchange differences </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:15.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> (1,022) </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:15.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> (728) </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:13.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 554 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:13.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;"> 28 </td> </tr> <tr> <td valign="bottom" style="width:33.80%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Finance cost lease liability </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:15.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> (6) </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:15.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> (6) </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:13.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> (13) </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:13.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;"> (13) </td> </tr> <tr> <td valign="bottom" style="width:33.80%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Other finance income/finance costs </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:15.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 71 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:15.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 208 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:13.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 166 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:13.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 448 </td> </tr> <tr> <td valign="bottom" style="width:33.80%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Gain from the modification of SVB Loan Agreement (see note 10) </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:15.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 62 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:15.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">  0 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:13.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 62 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:13.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;">  0 </td> </tr> <tr> <td valign="bottom" style="width:33.80%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Finance income/costs - net </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:15.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> (954) </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:15.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> (654) </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:13.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 653 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:13.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;"> 180 </td> </tr> </table></div>   <div /></div> </div> <div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:76.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:76.02%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:02.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:21.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;"> Outstanding balances </td> </tr> <tr> <td valign="bottom" style="width:76.02%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> June 30,  </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:09.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;"> December 31,  </td> </tr> <tr> <td valign="bottom" style="width:76.02%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">      </td> <td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:7pt;padding-right:2.25pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2020 </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">      </td> <td valign="bottom" style="width:09.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:7pt;padding-right:2.25pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2019 </td> </tr> <tr> <td valign="bottom" style="width:76.02%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Adi Hoess </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">  0 </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:09.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;">  5 </td> </tr> <tr> <td valign="bottom" style="width:76.02%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Wolfgang Fischer </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">  0 </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:09.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;">  1 </td> </tr> <tr> <td valign="bottom" style="width:76.02%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Dr. Thomas Hecht </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 19 </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:09.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;"> 26 </td> </tr> <tr> <td valign="bottom" style="width:76.02%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Berndt Modig </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">  9 </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:09.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;">  9 </td> </tr> <tr> <td valign="bottom" style="width:76.02%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Ferdinand Verdonck </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 11 </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:09.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;"> 11 </td> </tr> <tr> <td valign="bottom" style="width:76.02%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Dr. Ulrich Grau </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 17 </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:09.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;"> 21 </td> </tr> <tr> <td valign="bottom" style="width:76.02%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Dr. Bernhard Ehmer </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 16 </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:09.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;"> 20 </td> </tr> <tr> <td valign="bottom" style="width:76.02%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Mathieu Simon </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">  8 </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:09.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;">  9 </td> </tr> </table></div>   <div /></div> </div> 5000000000 38667000 40502000 133000 164000 P15D false --12-31 Q2 2020 2020-06-30 6-K 0001608390 Affimed N.V.

-70000

-125000

-2586000

228000

-649000

423000

551000

180000

653000

9000

4000

-9484000

-11757000

1167000

1410000

5000

9000

20000

11000

9000

26000

21000

1000

9000

16000

11000

8000

19000

17000

112359000

101148000

-0.14

-0.17

-0.26

-0.16

5000000

2500000

562000

368000

323000

0.055

270451000

292720000

94829000

63987000

95234000

84584000

-1280000

19646000

-10411000

811000

-18941000

-31538000

-18995000

-31750000

-7083000

-19219000

-8464000

-10389000

-20517000

-12309000

59314000

51739000

105914000

95069000

2105000

1039000

21353000

23911000

532000

451000

35181000

32491000

93000

92000

500000

2022-01-01

2020-01-01

2022-01-01

2020-01-01

2022-01-01

2020-01-01

2020-06-01

2022-01-01

<div> <div> Fair Value Measurement All assets and liabilities for which fair value is recognized in the interim financial statements are classified in accordance with the following fair value hierarchy, based on the lowest level input parameter that is significant on the whole for fair value measurement: <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"></td><td valign="top" align="left" style="width: 14.00pt;"> · </td><td style="width:14pt;"></td><td align="left" valign="top"> Level 1 – Prices for identical assets or liabilities quoted in active markets (non-adjusted)</td></tr></table></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"></td><td valign="top" align="left" style="width: 14.00pt;"> · </td><td style="width:14pt;"></td><td align="left" valign="top"> Level 2 – Measurement procedures, in which the lowest level input parameter significant on the whole for fair value measurement is directly or indirectly observable for on the market</td></tr></table></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"></td><td valign="top" align="left" style="width: 14.00pt;"> · </td><td style="width:14pt;"></td><td align="left" valign="top"> Level 3 – Measurement procedures, in which the lowest level input parameter significant on the whole for fair value measurement is not directly or indirectly observable for on the market</td></tr></table></div> The carrying amount of all trade and other receivables, certificates of deposit, cash and cash equivalents and trade and other payables is a reasonable approximation of the fair value and, therefore, information about the fair values of those financial instruments has not been disclosed. The measurement of the fair value of the shares held by the group and note disclosure for the fair value of a loan (financial liability) is based on level 2 measurement procedures (see notes 5 and 10). <div /></div> </div>

<div> <div> Functional and presentation currency These interim financial statements are presented in Euro, which is the Company’s functional currency. All financial information presented in Euro has been rounded to the nearest thousand (abbreviated €) or million (abbreviated € million). <div /></div> </div>

<div> <div> New standards and interpretations not yet adopted The following standards, amendments to standards and interpretations are effective for annual periods beginning after December 31, 2019 and have not been applied in preparing these consolidated financial statements. <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;font-family:Arial,Helvetica,sans-serif;"> <tr> <td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:60.28%;padding:0pt;"> Standard/interpretation </td> <td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:39.72%;padding:0pt;"> Effective Date </td> </tr> <tr> <td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:60.28%;padding:0pt;">   </td> <td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:39.72%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:60.28%;padding:0pt;"> Amendments to IAS 1 Presentation of Financial Statements: </td> <td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:39.72%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:60.28%;padding:0pt;"> Classification of Liabilities as Current or Non-current </td> <td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:39.72%;padding:0pt;"> January 1, 2022 </td> </tr> <tr> <td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:60.28%;padding:0pt;"> Amendments to IFRS 3 Business Combinations </td> <td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:39.72%;padding:0pt;"> January 1, 2022 </td> </tr> <tr> <td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:60.28%;padding:0pt;"> Amendments to IAS 16 Property, Plant and Equipment </td> <td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:39.72%;padding:0pt;"> January 1, 2022 </td> </tr> <tr> <td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:60.28%;padding:0pt;"> Amendments to AS 37 Provisions, Contingent Liabilities and Contingent Assets </td> <td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:39.72%;padding:0pt;"> January 1, 2022 </td> </tr> <tr> <td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:60.28%;padding:0pt;"> Annual Improvements 2018-2020 </td> <td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:39.72%;padding:0pt;"> January 1, 2022 </td> </tr> </table></div>   <div /></div> </div>

0.82

0.91

<div> <div> New standards and interpretations applied for the first time The following amendments to standards and new or amended interpretations are effective for annual periods beginning on or after January 1, 2020, and have been applied  in preparing these financial statements: <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;font-family:Arial,Helvetica,sans-serif;"> <tr> <td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:70.56%;padding:0pt;"> Standard/interpretation </td> <td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:29.44%;padding:0pt;"> Effective Date </td> </tr> <tr> <td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:70.56%;padding:0pt;">   </td> <td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:29.44%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:70.56%;padding:0pt;"> Amendments to References to the Conceptional Framework </td> <td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:29.44%;padding:0pt;"> January 1, 2020 </td> </tr> <tr> <td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:70.56%;padding:0pt;"> Amendments to IAS 1 and IAS 8: Definition of Material </td> <td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:29.44%;padding:0pt;"> January 1, 2020 </td> </tr> <tr> <td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:70.56%;padding:0pt;"> Amendments to IFRS 9, IAS 39 and IFRS 7: Interest Rate Benchmark Reform </td> <td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:29.44%;padding:0pt;"> January 1, 2020 </td> </tr> <tr> <td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:70.56%;padding:0pt;"> Amendments to IFRS 3 Business Combination </td> <td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:29.44%;padding:0pt;"> January 1, 2020 </td> </tr> <tr> <td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:70.56%;padding:0pt;"> Amendment to IFRS 16 Leases Covid 19-Related Rent Concessions </td> <td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:29.44%;padding:0pt;"> June 1, 2020 </td> </tr> <tr> <td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:70.56%;padding:0pt;">   </td> <td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:29.44%;padding:0pt;">   </td> </tr> </table></div>   None of the amendments to standards and new or amended interpretations had a material effect on the interim financial statements.   <div /></div> </div>

5.83

5.90

0.0214

0.0130

<div> <div> Critical judgments and accounting estimates The preparation of the interim financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. In preparing these interim financial statements, the critical judgments made by management in applying the Company’s accounting policies were the same as those that applied to the consolidated financial statements as of and for the year ended December 31, 2019. <div /></div> </div>

<div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:48.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:48.32%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Geographic information </td> <td valign="bottom" style="width:01.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">    </td> <td valign="bottom" style="width:01.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">    </td> <td valign="bottom" style="width:01.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">    </td> <td valign="bottom" style="width:01.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:48.32%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Three months </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Three months </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Six months </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;"> Six months </td> </tr> <tr> <td valign="bottom" style="width:48.32%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> ended </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> ended </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> ended </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;"> ended </td> </tr> <tr> <td valign="bottom" style="width:48.32%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">      </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> June 30, 2020 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">      </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> June 30, 2019 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">      </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> June 30, 2020 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">      </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;"> June 30, 2019 </td> </tr> <tr> <td valign="bottom" style="width:48.32%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Revenue: </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">    </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">    </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">    </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:48.32%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Germany </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">  0 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">  0 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 75 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;">  0 </td> </tr> <tr> <td valign="bottom" style="width:48.32%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Europe </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">  0 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 325 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">  2 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;"> 1,077 </td> </tr> <tr> <td valign="bottom" style="width:48.32%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> USA </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 2,934 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 3,683 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 7,992 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;"> 14,284 </td> </tr> <tr> <td valign="bottom" style="width:48.32%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 2,934 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 4,008 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 8,069 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;"> 15,361 </td> </tr> </table></div>   <div /></div> </div> <div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:48.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:48.32%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Major service lines </td> <td valign="bottom" style="width:01.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">    </td> <td valign="bottom" style="width:01.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">      </td> <td valign="bottom" style="width:11.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">    </td> <td valign="bottom" style="width:01.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">      </td> <td valign="bottom" style="width:11.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">    </td> <td valign="bottom" style="width:01.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">      </td> <td valign="bottom" style="width:11.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:48.32%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Three months </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Three months </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Six months </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;"> Six months </td> </tr> <tr> <td valign="bottom" style="width:48.32%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> ended </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> ended </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> ended </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;"> ended </td> </tr> <tr> <td valign="bottom" style="width:48.32%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">      </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> June 30, 2020 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">      </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> June 30, 2019 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">      </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> June 30, 2020 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">      </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;"> June 30, 2019 </td> </tr> <tr> <td valign="bottom" style="width:48.32%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:48.32%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Collaboration revenue </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 2,793 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 3,683 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 7,716 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;"> 14,284 </td> </tr> <tr> <td valign="bottom" style="width:48.32%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Service revenue </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 141 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 325 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 353 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;"> 1,077 </td> </tr> <tr> <td valign="bottom" style="width:48.32%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 2,934 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 4,008 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 8,069 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;"> 15,361 </td> </tr> </table></div>   <div /></div> </div> <div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:33.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:15.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:15.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:13.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:13.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.20%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Timing on revenue recognition </td> <td valign="bottom" style="width:01.88%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:15.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:15.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:13.86%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:13.86%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.20%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:15.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Three months ended </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">    </td> <td valign="bottom" style="width:15.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Three months ended </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">    </td> <td valign="bottom" style="width:13.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Six months ended </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">    </td> <td valign="bottom" style="width:13.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;"> Six months ended </td> </tr> <tr> <td valign="bottom" style="width:33.20%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">      </td> <td valign="bottom" style="width:15.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> June 30, 2020 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">      </td> <td valign="bottom" style="width:15.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> June 30, 2019 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">      </td> <td valign="bottom" style="width:13.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> June 30, 2020 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">      </td> <td valign="bottom" style="width:13.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;"> June 30, 2019 </td> </tr> <tr> <td valign="bottom" style="width:33.20%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:15.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:15.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:13.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:13.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.20%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Point in time </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:15.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 106 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:15.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">  0 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:13.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 283 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:13.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;"> 5,633 </td> </tr> <tr> <td valign="bottom" style="width:33.20%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Over time </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:15.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 2,828 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:15.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 4,008 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:13.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 7,786 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:13.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;"> 9,728 </td> </tr> <tr> <td valign="bottom" style="width:33.20%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:15.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 2,934 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:15.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 4,008 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:13.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 8,069 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:13.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;"> 15,361 </td> </tr> </table></div>   <div /></div> </div>

<div> <div> 12.     Subsequent events Upon the achievement of a clinical milestone in July 2020 under its ongoing strategic collaboration with Genentech, Affimed is eligible to receive a payment in an undisclosed amount.   <div /></div> </div>

<div> <div> 4.     Finance income and finance costs <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:33.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:15.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:15.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:13.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:13.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.80%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:15.72%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Three months ended </td> <td valign="bottom" style="width:01.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:15.72%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Three months ended </td> <td valign="bottom" style="width:01.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:13.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Six months ended </td> <td valign="bottom" style="width:01.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:13.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;"> Six months ended </td> </tr> <tr> <td valign="bottom" style="width:33.80%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">      </td> <td valign="bottom" style="width:15.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> June 30, 2020 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">      </td> <td valign="bottom" style="width:15.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> June 30, 2019 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">      </td> <td valign="bottom" style="width:13.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> June 30, 2020 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">      </td> <td valign="bottom" style="width:13.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;"> June 30, 2019 </td> </tr> <tr> <td valign="bottom" style="width:33.80%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Interest SVB Loan Agreement </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:15.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> (59) </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:15.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> (128) </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:13.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> (116) </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:13.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;"> (283) </td> </tr> <tr> <td valign="bottom" style="width:33.80%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Foreign exchange differences </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:15.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> (1,022) </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:15.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> (728) </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:13.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 554 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:13.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;"> 28 </td> </tr> <tr> <td valign="bottom" style="width:33.80%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Finance cost lease liability </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:15.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> (6) </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:15.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> (6) </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:13.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> (13) </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:13.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;"> (13) </td> </tr> <tr> <td valign="bottom" style="width:33.80%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Other finance income/finance costs </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:15.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 71 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:15.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 208 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:13.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 166 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:13.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 448 </td> </tr> <tr> <td valign="bottom" style="width:33.80%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Gain from the modification of SVB Loan Agreement (see note 10) </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:15.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 62 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:15.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">  0 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:13.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 62 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:13.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;">  0 </td> </tr> <tr> <td valign="bottom" style="width:33.80%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Finance income/costs - net </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:15.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> (954) </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:15.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> (654) </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:13.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 653 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:13.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;"> 180 </td> </tr> </table></div>   <div /></div> </div>

<div> <div> 6.     Financial assets As of June 30, 2020 and December 31, 2019, financial assets consisted of U.S. Dollar denominated certificates of deposit with original maturities of more than three months. <div /></div> </div>

<div> <div> 1.     Reporting entity Affimed N.V. is a Dutch company with limited liability (naamloze vennootschap) and has its corporate seat in Amsterdam, the Netherlands. The consolidated financial statements are comprised of Affimed N.V., and its controlled (and wholly owned) subsidiaries Affimed GmbH, Heidelberg, Germany, AbCheck s.r.o., Plzen, Czech Republic, Affimed Inc., Delaware, USA and AbCheck Inc., Delaware, USA (together “Affimed”, the “Company“ or the “Group”). Affimed is a clinical-stage immuno-oncology company focused on discovering and developing highly targeted cancer immunotherapies. The Group’s product candidates represent an innovative approach to cancer treatment that seeks to harness the body’s own immune defenses to fight tumor cells. Affimed has its own research and development programs, strategic collaborations and service contracts, pursuant to which Affimed is performing research services for third parties. <div /></div> </div>

<div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:65.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:03.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:65.30%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:02.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> June 30, 2020 </td> <td valign="bottom" style="width:03.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.76%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> June 30, 2019 </td> <td valign="bottom" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:65.30%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">      </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:03.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;">      </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:65.30%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Fair value at grant date </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 1.81 </td> <td valign="bottom" style="width:03.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 2.11 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:65.30%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Share price at grant date </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 2.50 </td> <td valign="bottom" style="width:03.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 3.04 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:65.30%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Exercise price </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 2.50 </td> <td valign="bottom" style="width:03.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 3.04 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:65.30%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Expected volatility </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 91 </td> <td valign="bottom" style="width:03.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;"> %   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 82 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;"> % </td> </tr> <tr> <td valign="bottom" style="width:65.30%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Expected life </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 5.90 </td> <td valign="bottom" style="width:03.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:2.4pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5.83 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:65.30%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Expected dividends </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 0.00 </td> <td valign="bottom" style="width:03.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 0.00 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:65.30%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Risk-free interest rate </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 1.30 </td> <td valign="bottom" style="width:03.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;"> %   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 2.14 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;"> % </td> </tr> </table></div>   <div /></div> </div>

<div> <div> 7.     Equity As of June 30, 2020 the share capital of €845 (December 31, 2019: €762) is divided into 84,493,155 (December 31, 2019: 76,249,901) common shares with a par value of €0.01 per share. In May 2020, the Company implemented an at-the-market ("ATM") program providing for the sales over time of up to $50,000,000 of its common shares. As of June 30, 2020, the Company has issued approximately 8.1 million common shares under this ATM program, generating net proceeds of approximately €21 million. <div /></div> </div>

<div> <div> 9.     Provisions In 2019, the group recognized costs related to the termination of the AFM 11 program totalling to €1.4 million, whereof €0.9 million were already incurred in 2019. Estimated costs expected to be incurred in future periods were recognized in provisions  (€0.5 million, December 31, 2019:  €0.5 million). <div /></div> </div>

<div> <div> 11.     Related parties The supervisory directors of Affimed N.V. received compensation for their services on the supervisory board of €96 and €181  (€100 and €195) in the three and six months ended June 30, 2020 (2019), remuneration of managing directors and other key management personnel amounted to €593 and €1,198  (€708 and €1,414). The payments in the six months ended June 30, 2020 include payments following the death of our former Chief Financial Officer, Florian Fischer, amounting to €120. The Company recognized share-based payment expenses of €17 and €53  (€19 and €40) for supervisory directors and €361 and €721  (€320 and €723) for managing directors and other key management personnel in the three and six months ended June 30, 2020 (2019). The following table provides the outstanding balances for management and supervisory board remuneration. <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:76.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:76.02%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:02.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:21.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;"> Outstanding balances </td> </tr> <tr> <td valign="bottom" style="width:76.02%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> June 30,  </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:09.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;"> December 31,  </td> </tr> <tr> <td valign="bottom" style="width:76.02%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">      </td> <td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:7pt;padding-right:2.25pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2020 </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">      </td> <td valign="bottom" style="width:09.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:7pt;padding-right:2.25pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2019 </td> </tr> <tr> <td valign="bottom" style="width:76.02%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Adi Hoess </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">  0 </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:09.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;">  5 </td> </tr> <tr> <td valign="bottom" style="width:76.02%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Wolfgang Fischer </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">  0 </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:09.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;">  1 </td> </tr> <tr> <td valign="bottom" style="width:76.02%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Dr. Thomas Hecht </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 19 </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:09.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;"> 26 </td> </tr> <tr> <td valign="bottom" style="width:76.02%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Berndt Modig </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">  9 </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:09.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;">  9 </td> </tr> <tr> <td valign="bottom" style="width:76.02%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Ferdinand Verdonck </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 11 </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:09.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;"> 11 </td> </tr> <tr> <td valign="bottom" style="width:76.02%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Dr. Ulrich Grau </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 17 </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:09.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;"> 21 </td> </tr> <tr> <td valign="bottom" style="width:76.02%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Dr. Bernhard Ehmer </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 16 </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:09.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;"> 20 </td> </tr> <tr> <td valign="bottom" style="width:76.02%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Mathieu Simon </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">  8 </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:09.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;">  9 </td> </tr> </table></div>   <div /></div> </div>

<div> <div> 3.     Revenue Collaboration agreement The Leukemia & Lymphoma Society (LLS) Affimed is party to a collaboration with LLS to fund the development of  specific product candidates (immune cell engagers). Under the terms of the agreement, LLS has agreed to contribute up to $4.4 million contingent upon the achievement of certain milestones. In the event that the research and development is successful, Affimed must proceed with commercialization of the licensed product. If Affimed decides for business reasons not to continue the commercialization, Affimed must at its option either repay the amount funded or grant a license to LLS to enable LLS to continue with the development program. In addition, LLS is entitled to receive royalties from Affimed based on the Group’s future revenue from any licensed product, with the amount of royalties not to exceed three times the amount funded. In June 2016, the research funding agreement with LLS was amended to reflect a shift to the development of combination therapeutic approaches so that the milestones now relate primarily to the development of a combination therapy. During the six months ended June 30, 2020, the Company recognized revenue totalling €0.1 million (2019:  €0 million). Collaboration with Genentech Inc. In August 2018, Affimed entered into a strategic collaboration agreement with Genentech Inc., headquartered in South San Francisco, USA. Under the terms of the agreement Affimed will develop novel NK cell engager-based immunotherapeutics to treat multiple cancers. The Genentech agreement became effective at the beginning of October 2018. Affimed received $96.0 million (€83.2 million) in initial upfront and committed funding on October 31, 2018. The Group recognized €2.7 million and €7.6 million as revenue during the three and six months ended June 30, 2020 (2019: €3.7 million and €14.3 million). As of June 30, 2020, contract liabilities of €51.7 million (December 31, 2019: €59.3 million) will be recognized as revenue in subsequent periods. Under the terms of the agreement, Affimed is eligible to receive up to an additional $5.0 billion over time, including payments upon achievement of specified development, regulatory and commercial milestones. Affimed is also eligible to receive royalties on any potential sales. Research service agreements The Group, through its subsidiary AbCheck s.r.o. has entered into certain research service agreements. These research service agreements provide for non-refundable upfront technology access research funding or capacity reservation fees and milestone payments. The Company recognized €0.2 million and €0.4 million as revenue in the three and six months ended June 30, 2020 (2019: €0.3 million and €1.1 million). Contract balances The following table provides information about receivables and contract liabilities from contracts with customers. <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:64.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:13.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:18.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:64.04%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:02.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">      </td> <td valign="bottom" style="width:13.14%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;"> June 30, 2020 </td> <td valign="bottom" style="width:02.36%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">      </td> <td valign="bottom" style="width:18.16%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;"> December 31, 2019 </td> </tr> <tr> <td valign="bottom" style="width:64.04%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:13.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:18.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:64.04%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Receivables </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:13.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;"> 45 </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:18.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;"> 204 </td> </tr> <tr> <td valign="bottom" style="width:64.04%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Contract liabilities </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:13.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;"> 51,739 </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:18.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;"> 59,314 </td> </tr> </table></div>   Amounts of €2,749 and €7,580 recognized in contract liabilities at the beginning of the period have been recognized as revenue during the three and six months ended June 30, 2020. The remaining performance obligations as of June 30, 2020 are approximately €51.7 million and are expected to be recognized as revenue to a large extent over the next two years. Disaggregation of revenue <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:48.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:48.32%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Geographic information </td> <td valign="bottom" style="width:01.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">    </td> <td valign="bottom" style="width:01.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">    </td> <td valign="bottom" style="width:01.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">    </td> <td valign="bottom" style="width:01.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:48.32%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Three months </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Three months </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Six months </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;"> Six months </td> </tr> <tr> <td valign="bottom" style="width:48.32%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> ended </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> ended </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> ended </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;"> ended </td> </tr> <tr> <td valign="bottom" style="width:48.32%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">      </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> June 30, 2020 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">      </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> June 30, 2019 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">      </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> June 30, 2020 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">      </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;"> June 30, 2019 </td> </tr> <tr> <td valign="bottom" style="width:48.32%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Revenue: </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">    </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">    </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">    </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:48.32%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Germany </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">  0 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">  0 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 75 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;">  0 </td> </tr> <tr> <td valign="bottom" style="width:48.32%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Europe </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">  0 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 325 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">  2 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;"> 1,077 </td> </tr> <tr> <td valign="bottom" style="width:48.32%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> USA </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 2,934 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 3,683 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 7,992 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;"> 14,284 </td> </tr> <tr> <td valign="bottom" style="width:48.32%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 2,934 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 4,008 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 8,069 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;"> 15,361 </td> </tr> </table></div>   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:48.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:48.32%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Major service lines </td> <td valign="bottom" style="width:01.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">    </td> <td valign="bottom" style="width:01.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">      </td> <td valign="bottom" style="width:11.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">    </td> <td valign="bottom" style="width:01.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">      </td> <td valign="bottom" style="width:11.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">    </td> <td valign="bottom" style="width:01.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">      </td> <td valign="bottom" style="width:11.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:48.32%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Three months </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Three months </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Six months </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;"> Six months </td> </tr> <tr> <td valign="bottom" style="width:48.32%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> ended </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> ended </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> ended </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;"> ended </td> </tr> <tr> <td valign="bottom" style="width:48.32%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">      </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> June 30, 2020 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">      </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> June 30, 2019 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">      </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> June 30, 2020 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">      </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;"> June 30, 2019 </td> </tr> <tr> <td valign="bottom" style="width:48.32%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:48.32%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Collaboration revenue </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 2,793 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 3,683 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 7,716 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;"> 14,284 </td> </tr> <tr> <td valign="bottom" style="width:48.32%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Service revenue </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 141 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 325 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 353 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;"> 1,077 </td> </tr> <tr> <td valign="bottom" style="width:48.32%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 2,934 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 4,008 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 8,069 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;"> 15,361 </td> </tr> </table></div>   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:33.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:15.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:15.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:13.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:13.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.20%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Timing on revenue recognition </td> <td valign="bottom" style="width:01.88%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:15.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:15.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:13.86%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:13.86%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.20%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:15.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Three months ended </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">    </td> <td valign="bottom" style="width:15.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Three months ended </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">    </td> <td valign="bottom" style="width:13.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Six months ended </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">    </td> <td valign="bottom" style="width:13.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;"> Six months ended </td> </tr> <tr> <td valign="bottom" style="width:33.20%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">      </td> <td valign="bottom" style="width:15.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> June 30, 2020 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">      </td> <td valign="bottom" style="width:15.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> June 30, 2019 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">      </td> <td valign="bottom" style="width:13.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> June 30, 2020 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">      </td> <td valign="bottom" style="width:13.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;"> June 30, 2019 </td> </tr> <tr> <td valign="bottom" style="width:33.20%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:15.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:15.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:13.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:13.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.20%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Point in time </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:15.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 106 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:15.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">  0 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:13.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 283 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:13.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;"> 5,633 </td> </tr> <tr> <td valign="bottom" style="width:33.20%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Over time </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:15.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 2,828 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:15.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 4,008 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:13.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 7,786 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:13.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;"> 9,728 </td> </tr> <tr> <td valign="bottom" style="width:33.20%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:15.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 2,934 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:15.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 4,008 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:13.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 8,069 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:13.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;"> 15,361 </td> </tr> </table></div>   <div /></div> </div>

<div> <div> 8.     Share-based payments In 2014, an equity-settled share-based payment program was established by Affimed N.V. (ESOP 2014). Under this program, the Company granted awards to certain members of the Management Board, the Supervisory Board, non-employee consultants and employees. Share based payments with service condition The majority of the awards vest in instalments over three years and can be exercised up to 10 years after the grant date. In the three and six months ended June 30, 2020, the group granted 478,750 and 1,388,559 awards. 58,729 and 183,141 ESOP 2014 awards were cancelled or forfeited, and 197,007 options were exercised during the three and six months ended June 30, 2020. As of June 30, 2020, 8,315,978 ESOP 2014 options (December 31, 2019: 7,307,567) were outstanding, and 5,623,642 awards (December 31, 2019: 4,773,840) had vested. The options outstanding as of June 30, 2020 had an exercise price in the range of $1.30 to $13.47. Share based payments with market condition On April 20, 2018, Affimed issued 240,000 options, of which each grant consists of three tranches that vest when the volume-weighted average share price (measured based on Affimed closing share prices over the preceding fifteen trading days) reaches a certain hurdle ($6.15,  $8.20 and $10.25). Fair value of the awards at grant date amounts to €133  ($164 thousand) and the contractual life time of the options was two years. No options were exercisable and the term of the options has been expired. Share based payment expense In the three and six months ended June 30, 2020, compensation expense of €684 and €1,410 was recognized affecting research and development expenses (€400 and €717) and general and administrative expenses (€284 and €693). In the three and six months ended June 30, 2019, compensation expense of €566 and €1,167 was recognized affecting research and development expenses (€231 and €500) and general and administrative expenses (€335 and €667). Fair value measurement The fair value of options was determined using the Black-Scholes valuation model. The significant inputs into the valuation model of share based payment grants with service conditions are as follows (weighted average): <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:65.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:03.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:65.30%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:02.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> June 30, 2020 </td> <td valign="bottom" style="width:03.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.76%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> June 30, 2019 </td> <td valign="bottom" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:65.30%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">      </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:03.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;">      </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:65.30%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Fair value at grant date </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 1.81 </td> <td valign="bottom" style="width:03.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 2.11 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:65.30%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Share price at grant date </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 2.50 </td> <td valign="bottom" style="width:03.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 3.04 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:65.30%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Exercise price </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 2.50 </td> <td valign="bottom" style="width:03.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 3.04 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:65.30%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Expected volatility </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 91 </td> <td valign="bottom" style="width:03.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;"> %   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 82 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;"> % </td> </tr> <tr> <td valign="bottom" style="width:65.30%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Expected life </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 5.90 </td> <td valign="bottom" style="width:03.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:2.4pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5.83 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:65.30%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Expected dividends </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 0.00 </td> <td valign="bottom" style="width:03.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 0.00 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:65.30%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> Risk-free interest rate </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 1.30 </td> <td valign="bottom" style="width:03.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;"> %   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;">   </td> <td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #ABC8EB;padding:0pt;"> 2.14 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #ABC8EB;padding:0pt;"> % </td> </tr> </table></div>   Expected volatility is estimated based on the observed daily share price returns of a peer group measured over a historic period equal to the expected life of the awards. The risk-free interest rates are based on the yield to maturity of U.S. Treasury strips and German sovereign strips respectively (as best available indication for risk-free rates), for a term equal to the expected life, as measured as of the Grant Date. <div /></div> </div>

-210000

431000

40129000

239055000

624000

-202144000

2594000

32845000

240235000

624000

-210632000

2618000

38667000

270451000

762000

-234508000

1962000

40502000

292720000

845000

-255035000

1972000

112359000

101148000

3.04

2.50

1.30

13.47

0.00

1167000

667000

723000

500000

40000

566000

335000

320000

231000

19000

1410000

693000

721000

717000

53000

684000

284000

361000

400000

17000

3200000

180000

-13000

28000

-283000

448000

-654000

-6000

-728000

-128000

208000

653000

-13000

554000

62000

-116000

62000

166000

-954000

-6000

-1022000

62000

-59000

71000

2013000

947000

24000

10000

4776000

2342000

6131000

2606000

4000

-30632000

-11081000

13000

192000

1167000

1410000

137000

103000

134000

64000

188000

276000

296000

421000

762000

845000

20942000

20859000

83000

120000

278000

231000

49000

71000

6445000

6079000

37961000

27829000

3193000

3203000

272000

95000

38511000

28155000

1388559

478750

4773840

5623642

183141

58729

7307567

8315978

240000

50000000

8100000

76249901

84493155

24000

10000

24000

-49000

10000

-71000

8902000

8037000

2013000

947000

283000

197000

28000

85000

1962000

1972000

0.01

754000

206000

257000

562000

25748000

9088000

13000

21785000

-8488000

-10340000

-20527000

-12238000

-8484000

-10336000

-20527000

-12238000

-8664000

-9682000

-21180000

-11284000

2291000

2237000

517000

484000

35262000

8101000

142000

2000

755000

174000

204000

45000

1649000

1128000

127000

19532000

11545000

23146000

11697000

-234508000

-255035000

15361000

4008000

8069000

2934000

15361000

14284000

1077000

14284000

5633000

9728000

1077000

4008000

3683000

325000

3683000

4008000

325000

8069000

7716000

353000

75000

7992000

283000

7786000

2000

2934000

2793000

141000

2934000

106000

2828000

1100000

14300000

300000

3700000

400000

7600000

100000

200000

2700000

59300000

7580000

51700000

2749000

824000

536000

<div> <div> Statement of compliance The interim financial statements for the three and six months ended June 30, 2020 and 2019 have been prepared in accordance with IAS 34 Interim Financial Reporting. The interim financial statements do not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with Affimed N.V.’s annual consolidated financial statements as of December 31, 2019. The interim financial statements were authorized for issuance by the management board on August 11, 2020. <div /></div> </div>

Amendments to AS 37 Provisions, Contingent Liabilities and Contingent Assets

Amendments to IAS 16 Property, Plant and Equipment

Amendments to IAS 1 and IAS 8: Definition of Material

Classification of Liabilities as Current or Non-current

Amendments to IFRS 3 Business Combination

Amendments to IFRS 3 Business Combinations

Amendments to IFRS 9, IAS 39 and IFRS 7: Interest Rate Benchmark Reform

Amendments to References to the Conceptional Framework

Amendment to IFRS 16 Leases Covid 19-Related Rent Concessions

Annual Improvements 2018-2020

10674000

6606000

1482000

2027000

51700000

2500000

2.11

1.81

10.25

8.20

6.15

3.04

2.50

62434734

62439363

77719793

79189686

EX-101.SCH 6 afmd-20200630.xsd EX-101.SCH 00100 - Statement - Consolidated statements of comprehensive income / (loss) link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - Consolidated statements of financial position link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - Consolidated Statement of Cash Flows link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - Consolidated Statement of Changes in Equity link:presentationLink link:calculationLink link:definitionLink 20202 - Disclosure - Basis of preparation and changes to Group's accounting policies (Policies) link:presentationLink link:calculationLink link:definitionLink 40201 - Disclosure - Basis of preparation and changes to Group's accounting policies (Details) link:presentationLink link:calculationLink link:definitionLink 40202 - Disclosure - Basis of preparation and changes to Group's accounting policies - New standards and interpretations not yet adopted (Details) link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - Revenue - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 40303 - Disclosure - Revenue - Disaggregation of revenue (Details) link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - Finance income and finance costs (Details) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Long term financial assets (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - Equity (Details) link:presentationLink link:calculationLink link:definitionLink 40802 - Disclosure - Share-based payments - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 41001 - Disclosure - Borrowings - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 41101 - Disclosure - Related parties - Outstanding Balances (Details) link:presentationLink link:calculationLink link:definitionLink 41102 - Disclosure - Related parties - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - Reporting entity link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Basis of preparation and changes to Group's accounting policies link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Revenue link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Finance income and finance costs link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Long term financial assets link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Financial assets link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - Equity link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - Share-based payments link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - Provisions link:presentationLink link:calculationLink link:definitionLink 11001 - Disclosure - Borrowings link:presentationLink link:calculationLink link:definitionLink 11101 - Disclosure - Related parties link:presentationLink link:calculationLink link:definitionLink 11201 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 30203 - Disclosure - Basis of preparation and changes to Group's accounting policies (Tables) link:presentationLink link:calculationLink link:definitionLink 30303 - Disclosure - Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 30403 - Disclosure - Finance income and finance costs (Tables) link:presentationLink link:calculationLink link:definitionLink 30803 - Disclosure - Share-based payments (Tables) link:presentationLink link:calculationLink link:definitionLink 31103 - Disclosure - Related parties (Tables) link:presentationLink link:calculationLink link:definitionLink 40302 - Disclosure - Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Financial assets (Details) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - Share-based payments (Details) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - Provisions (Details) link:presentationLink link:calculationLink link:definitionLink 41002 - Disclosure - Borrowings - Movements of Liabilities Reconcile to Cash Flows Arising from Financing Activities (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 afmd-20200630_cal.xml EX-101.CAL EX-101.DEF 8 afmd-20200630_def.xml EX-101.DEF EX-101.LAB 9 afmd-20200630_lab.xml EX-101.LAB Document and Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Period Focus consolidated statements of comprehensive income / (loss) Revenue Other operating income (expense) Other income - net Research and development expenses. Research and development expenses General and administrative expense General and administrative expenses Profit (loss) from operating activities Operating income / (loss) Finance income (cost) Finance income/costs - net Profit (loss) before tax Income / (loss) before tax Tax expense (income), continuing operations Income taxes Loss for the period Income / (loss) for the period Income / (loss) for the period Components of other comprehensive income that will not be reclassified to profit or loss, net of tax [abstract] Other comprehensive income / (loss) Items that will not be reclassified to profit or loss Other comprehensive income, net of tax, gains (losses) from investments in equity instruments Equity investments at fair value OCI - net change in fair value Other comprehensive income loss Other Comprehensive Income Loss Other comprehensive income / (loss) Total comprehensive loss Total comprehensive income / (loss) Earnings / (loss) per share in per share (undiluted = diluted) Earnings / (loss) per share in per share (undiluted = diluted) Weighted average number of ordinary shares outstanding Weighted number of common shares outstanding Consolidated statements of financial position ASSETS Non-current assets Intangible assets other than goodwill Intangible assets Leasehold improvements and equipment Non-current financial assets Long term financial assets Right-of-use assets Right-of-use assets Non-current assets [Default Label] Total non-current assets Current assets Cash and cash equivalents Cash and cash equivalents at the end of the period Cash and cash equivalents at the beginning of the period Cash and cash equivalents at the end of the year Other current financial assets Financial assets Trade and other current receivables Trade and other receivables Inventories Current assets [Default Label] Total current assets TOTAL ASSETS TOTAL ASSETS EQUITY AND LIABILITIES Equity Issued Capital. Issued capital Capital reserve. Capital reserves Other reserves Fair value reserves Retained earnings Accumulated deficit Equity attributable to owners of parent Sum controlling interests Equity Total Equity Total equity Non current liabilities Non-current portion of non-current borrowings Borrowings Non-current contract liabilities Contract liabilities Non-current lease liabilities Lease liabilities Non-current liabilities Total non-current liabilities Current liabilities Trade and other payables Trade and other payables Provisions. Provisions Current borrowings and current portion of non-current borrowings Borrowings Current lease liabilities Lease liabilities Current contract liabilities Contract liabilities Current liabilities [Default Label] Total current liabilities Equity and liabilities. TOTAL EQUITY AND LIABILITIES Statement of cash flows [abstract] Cash flow from operating activities Adjustments for the period: Adjustments for income tax expense Income taxes Depreciation and amortisation Net gain from disposal of leasehold improvements and equipment Net gain from disposal of leasehold improvements and equipment Adjustments for share-based payments Share based payments Finance income / costs - net Finance income / costs - net Cash flows from (used in) operations before changes in working capital Total Change in trade and other receivables Change in trade and other receivables Change in inventories Change in inventories Change in other assets Change in other assets Change in trade, other payables, provisions and contract liabilities Change in trade, other payables, provisions and contract liabilities Cash flows from (used in) operations Cash used in operating activities Interest received Interest received Interest paid, classified as operating activities Paid interest Cash flows from (used in) operating activities Net cash used in operating activities Cash flow from investing activities Purchase of intangible assets, classified as investing activities Purchase of intangible assets Purchase of property, plant and equipment, classified as investing activities Purchase of leasehold improvements and equipment Purchase of available-for-sale financial assets Cash paid for investments in financial assets Cash received from maturity of financial assets Cash flows from (used in) investing activities Net cash used for investing activities Cash flow from financing activities Proceeds from issue of common shares Proceeds from issue of common shares Payments for share issue costs Transaction costs related to issue of common shares Proceeds from borrowings Proceeds from borrowings Payments of lease liabilities, classified as financing activities Repayment of lease liabilities Repayments of borrowings, classified as financing activities Repayment of borrowings Cash flows from (used in) financing activities Cash flow from financing activities Exchange-rate related changes of cash and cash equivalents Exchange-rate related changes of cash and cash equivalents Increase (decrease) in cash and cash equivalents before effect of exchange rate changes Net changes to cash and cash equivalents Statement of changes in equity Statement of changes in equity [table] Components of equity [axis] Equity [Member] Equity [member] Issued Capital [Member] Issued Capital Revaluation Surplus [Member] Fair Value Reserves Retained Earnings [Member] Accumulated Deficit Statement of changes in equity [line items] Equity [Default Label] Balance, ending Balance beginning Issue of common shares Exercise of share based payment awards Equity-settled share based payment awards Income loss Income Loss Loss for the period Other comprehensive income Other comprehensive income Reporting entity Disclosure of general information about financial statements [text block] Reporting entity Basis of preparation and changes to Group's accounting policies The disclosure of Basis of preparation and changes made to accounting policies by the entity. Basis of Preparation and Changes to Group's Accounting Policies [Text Block] Basis of preparation and changes to Group's accounting policies Revenue. Disclosure of revenue [text block] Revenue Finance income and finance costs Disclosure of finance income (cost) [text block] Finance income and finance costs Long term financial assets The entire disclosure of long term financial assets. Disclosure Of Long Term Financial Assets [Text Block] Long term financial assets Financial assets Disclosure of financial assets [text block] Financial assets Disclosure of issued capital [text block] Equity Share-based payments Disclosure of share-based payment arrangements [text block] Share-based payments Provisions Disclosure of provisions [text block] Provisions Borrowings Disclosure of borrowings [text block] Borrowings Related parties Disclosure of related party [text block] Related parties Subsequent Events Disclosure of events after reporting period [text block] Subsequent Events Disclosure of initial application of standards or interpretations [table] Disclosure of initial application of standards or interpretations [line items] Statement of IFRS compliance [text block] Statement of compliance Critical Judgments and Accounting Estimates Critical judgments and accounting estimates Description of accounting policy for functional currency [text block] Functional and presentation currency The description of significant accounting policies Description of Significant Accounting Policies [Text Block] Significant Accounting Policies New Standards and Interpretations Applied for the First Time New standards and interpretations applied for the first time Fair Value Measurement New Standards and Interpretations Not Yet Adopted New standards and interpretations not yet adopted Disclosure of contingent liabilities [text block] Schedule of contract liabilities from customer Disclosure of disaggregation of revenue from contracts with customers [text block] Schedule of Disaggregation of Revenue The tabular disclosure of finance income and costs. Schedule of Finance Income and Finance Costs [Table Text Block] Finance Income and finance Costs Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block] Assumptions of Options Granted Tabular disclosure of transaction amounts and outstanding balances. Summary Of Transaction and Outstanding Balances Related To Key Management Personnel [Table Text Block] Transaction and Outstanding Balances Related to Key Management Personnel Significant Accounting Policies Standard/amendment Date by which application of new IFRS is required Effective date for new standards and interpretations applied for the first time Disclosure of disaggregation of revenue from contracts with customers [table] Counterparties [axis] Counterparties [Member] Counterparties [member] This member represents information pertaining to leukemia & lymphoma society Leukemia And Lymphoma Society [Member] Leukemia & Lymphoma Society This member represents information pertaining to AbCheck Ab Check [Member] AbCheck Represents information pertaining to Genentech Inc. Genentech Inc [Member] Genentech Inc Other revenue information Revenue from rendering of services Revenue The amount of contingent payment upon achievement of certain milestone under the collaboration agreement. Collaboration Agreement, Contingent Payment Upon Achievement Of Certain Milestones Contingent payment upon achievement of certain milestone under the collaboration agreement The amount of initial upfront payment received. Collaboration Agreement, Initial Upfront Payment Collaboration agreement initial upfront payment received Revenue that was included in contract liability balance at beginning of period Revenue under contract liabilities The threshold amount that may be eligible to receive including payments upon achievement of specified development, regulatory and commercial milestones, and royalties on sales. Threshold Amount Eligible To Receive Overtime Upon Achievement Of Milestones Additional payments upon achievement of milestones Transaction price allocated to remaining performance obligations Remaining performance obligations Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. IFRS Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period Remaining performance obligation period Receivables from contracts with customers Receivables Contract liabilities Revenue from contracts with customers Revenues No definition available. Disclosure of Finance Income and Finance Costs Table] Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table. Disclosure of Finance Income and Finance Costs Line Items] Disclosure of financial assets [table] Classes of share capital [axis] Classes Of Share Capital [Member] Share capital [member] Preference Shares [Member] Preferred Shares Disclosure of financial assets [line items] Investments in equity instruments designated at fair value through other comprehensive income Fair value of preferred shares Gains (losses) on change in fair value of derivatives Increase in fair value Losses on change in fair value of derivatives Decrease in fair value Represents the minimum maturity period of certificate of deposits. Minimum Maturity Period Of Certificate Of Deposits Minimum Maturity period of certificate of deposits Represents the information pertaining to shares issued under at the market sales agreement. Shares Issued Under At Market Sales Agreement [Member] At-the-market sales agreement The value of shares authorized. Authorized Capital Authorized capital Number of shares outstanding Number of shares outstanding Par value Par value Number of shares issued Number of shares issued Number of shares authorised Number of common shares authorized to issue at the market Fair value at grant date Fair value at grant date Weighted average share price Share price at grant date Expected volatility Expected volatility Expected life Expected life Expected dividends Expected dividends Risk-free interest rate Risk-free interest rate Disclosure of terms and conditions of share-based payment arrangement [table] Types of share-based payment arrangements [axis] Sharebased Payment Arrangements [Member] Share-based payment arrangements [member] This member represents information pertaining to ESOP 2014 Esop2014 [Member] ESOP 2014 Nature of expenses [Axis] Nature Of Expenses [Domain] Nature Of Expenses [Domain] This member represents information pertaining to research and development Research And Development [Member] Research and Development EX-101.PRE 10 afmd-20200630_pre.xml EX-101.PRE GRAPHIC 11 g261761mqi001.jpg GRAPHIC begin 644 g261761mqi001.jpg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htm IDEA: XBRL DOCUMENT

Document and Entity Information	6 Months Ended
Document and Entity Information	Jun. 30, 2020
Document and Entity Information
Entity Registrant Name	Affimed N.V.
Entity Central Index Key	0001608390
Document Type	6-K
Document Period End Date	Jun. 30, 2020
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q2

XML 13 R2.htm IDEA: XBRL DOCUMENT

Consolidated statements of comprehensive income / (loss) - EUR (€) € in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
consolidated statements of comprehensive income / (loss)
Revenue	€ 2,934	€ 4,008	€ 8,069	€ 15,361
Other income - net	85	197	28	283
Research and development expenses	(11,697)	(11,545)	(23,146)	(19,532)
General and administrative expenses	(2,606)	(2,342)	(6,131)	(4,776)
Operating income / (loss)	(11,284)	(9,682)	(21,180)	(8,664)
Finance income/costs - net	(954)	(654)	653	180
Income / (loss) before tax	(12,238)	(10,336)	(20,527)	(8,484)
Income taxes	0	(4)	0	(4)
Income / (loss) for the period	(12,238)	(10,340)	(20,527)	(8,488)
Other comprehensive income / (loss) Items that will not be reclassified to profit or loss
Equity investments at fair value OCI - net change in fair value	(71)	(49)	10	24
Other comprehensive income / (loss)	(71)	(49)	10	24
Total comprehensive income / (loss)	€ (12,309)	€ (10,389)	€ (20,517)	€ (8,464)
Earnings / (loss) per share in per share (undiluted = diluted)	€ (0.16)	€ (0.17)	€ (0.26)	€ (0.14)
Weighted number of common shares outstanding	79,189,686	62,439,363	77,719,793	62,434,734

XML 14 R3.htm IDEA: XBRL DOCUMENT

Consolidated statements of financial position - EUR (€) € in Thousands	Jun. 30, 2020	Dec. 31, 2019
Non-current assets
Intangible assets	€ 103	€ 137
Leasehold improvements and equipment	2,237	2,291
Long term financial assets	3,203	3,193
Right-of-use assets	536	824
Total non-current assets	6,079	6,445
Current assets
Cash and cash equivalents	84,584	95,234
Financial assets	8,037	8,902
Trade and other receivables	2,027	1,482
Inventories	421	296
Total current assets	95,069	105,914
TOTAL ASSETS	101,148	112,359
Equity
Issued capital	845	762
Capital reserves	292,720	270,451
Fair value reserves	1,972	1,962
Accumulated deficit	(255,035)	(234,508)
Total equity	40,502	38,667
Non current liabilities
Borrowings	231	278
Contract liabilities	27,829	37,961
Lease liabilities	95	272
Total non-current liabilities	28,155	38,511
Current liabilities
Trade and other payables	6,606	10,674
Provisions	484	517
Borrowings	1,039	2,105
Lease liabilities	451	532
Contract liabilities	23,911	21,353
Total current liabilities	32,491	35,181
TOTAL EQUITY AND LIABILITIES	€ 101,148	€ 112,359

XML 15 R4.htm IDEA: XBRL DOCUMENT

Consolidated Statement of Cash Flows - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Cash flow from operating activities
Income / (loss) for the period	€ 20,527	€ 8,488
Adjustments for the period:
Income taxes	0	4
Depreciation and amortisation	551	423
Net gain from disposal of leasehold improvements and equipment	0	(9)
Share based payments	1,410	1,167
Finance income / costs - net	(653)	(180)
Total	(19,219)	(7,083)
Change in trade and other receivables	(649)	228
Change in inventories	(125)	(70)
Change in other assets	0	(2,586)
Change in trade, other payables, provisions and contract liabilities	(11,757)	(9,484)
Cash used in operating activities	(31,750)	(18,995)
Interest received	276	188
Paid interest	(64)	(134)
Net cash used in operating activities	(31,538)	(18,941)
Cash flow from investing activities
Purchase of intangible assets	(2)	(142)
Purchase of leasehold improvements and equipment	(174)	(755)
Cash paid for investments in financial assets	(8,101)	(35,262)
Cash received from maturity of financial assets	9,088	25,748
Net cash used for investing activities	811	(10,411)
Cash flow from financing activities
Proceeds from issue of common shares	21,785	13
Transaction costs related to issue of common shares	(754)	0
Proceeds from borrowings	0	562
Repayment of lease liabilities	(257)	(206)
Repayment of borrowings	(1,128)	(1,649)
Cash flow from financing activities	19,646	(1,280)
Exchange-rate related changes of cash and cash equivalents	431	(210)
Net changes to cash and cash equivalents	(11,081)	(30,632)
Cash and cash equivalents at the beginning of the period	95,234	94,829
Cash and cash equivalents at the end of the period	84,584	63,987
Cash and cash equivalents at the end of the year	€ 84,584	€ 63,987

XML 16 R5.htm IDEA: XBRL DOCUMENT

Consolidated Statement of Changes in Equity - EUR (€) € in Thousands	Issued Capital	Capital Reserves	Fair Value Reserves	Accumulated Deficit	Total
Balance beginning at Jan. 01, 2019	€ 624	€ 239,055	€ 2,594	€ (202,144)	€ 40,129
Exercise of share based payment awards		13			13
Equity-settled share based payment awards		1,167			1,167
Loss for the period				(8,488)	(8,488)
Other comprehensive income			24		24
Balance, ending at Jun. 30, 2019	624	240,235	2,618	(210,632)	32,845
Balance beginning at Jan. 01, 2020	762	270,451	1,962	(234,508)	38,667
Issue of common shares	83	20,859			20,942
Equity-settled share based payment awards		1,410			1,410
Loss for the period				(20,527)	(20,527)
Other comprehensive income			10		10
Balance, ending at Jun. 30, 2020	€ 845	€ 292,720	€ 1,972	€ (255,035)	€ 40,502

- Definition

The amount of residual interest in the assets of the entity after deducting all its liabilities.

+ References + Details

XML 17 R6.htm IDEA: XBRL DOCUMENT

Reporting entity	6 Months Ended
Reporting entity	Jun. 30, 2020
Reporting entity
Reporting entity	1. Reporting entity Affimed N.V. is a Dutch company with limited liability (naamloze vennootschap) and has its corporate seat in Amsterdam, the Netherlands. The consolidated financial statements are comprised of Affimed N.V., and its controlled (and wholly owned) subsidiaries Affimed GmbH, Heidelberg, Germany, AbCheck s.r.o., Plzen, Czech Republic, Affimed Inc., Delaware, USA and AbCheck Inc., Delaware, USA (together “Affimed”, the “Company“ or the “Group”). Affimed is a clinical-stage immuno-oncology company focused on discovering and developing highly targeted cancer immunotherapies. The Group’s product candidates represent an innovative approach to cancer treatment that seeks to harness the body’s own immune defenses to fight tumor cells. Affimed has its own research and development programs, strategic collaborations and service contracts, pursuant to which Affimed is performing research services for third parties.

XML 18 R7.htm IDEA: XBRL DOCUMENT

Basis of preparation and changes to Group's accounting policies

6 Months Ended

Jun. 30, 2020

Basis of preparation and changes to Group's accounting policies

Basis of preparation and changes to Group's accounting policies

2. Basis of preparation and changes to Group’s accounting policies

Statement of compliance

The interim financial statements were authorized for issuance by the management board on August 11, 2020.

Critical judgments and accounting estimates

Functional and presentation currency

Significant accounting policies

New standards and interpretations applied for the first time

Standard/interpretation	Effective Date

Amendments to References to the Conceptional Framework	January 1, 2020
Amendments to IAS 1 and IAS 8: Definition of Material	January 1, 2020
Amendments to IFRS 9, IAS 39 and IFRS 7: Interest Rate Benchmark Reform	January 1, 2020
Amendments to IFRS 3 Business Combination	January 1, 2020
Amendment to IFRS 16 Leases Covid 19-Related Rent Concessions	June 1, 2020

None of the amendments to standards and new or amended interpretations had a material effect on the interim financial statements.

Fair Value Measurement

Level 1 – Prices for identical assets or liabilities quoted in active markets (non-adjusted)

Level 2 – Measurement procedures, in which the lowest level input parameter significant on the whole for fair value measurement is directly or indirectly observable for on the market

Level 3 – Measurement procedures, in which the lowest level input parameter significant on the whole for fair value measurement is not directly or indirectly observable for on the market

New standards and interpretations not yet adopted

Standard/interpretation	Effective Date

Amendments to IAS 1 Presentation of Financial Statements:
Classification of Liabilities as Current or Non-current	January 1, 2022
Amendments to IFRS 3 Business Combinations	January 1, 2022
Amendments to IAS 16 Property, Plant and Equipment	January 1, 2022
Amendments to AS 37 Provisions, Contingent Liabilities and Contingent Assets	January 1, 2022
Annual Improvements 2018-2020	January 1, 2022

XML 19 R8.htm IDEA: XBRL DOCUMENT

Revenue

6 Months Ended

Jun. 30, 2020

Revenue.

Revenue

3. Revenue

Collaboration agreement The Leukemia & Lymphoma Society (LLS)

During the six months ended June 30, 2020, the Company recognized revenue totalling €0.1 million (2019: €0 million).

Collaboration with Genentech Inc.

Research service agreements

Contract balances

The following table provides information about receivables and contract liabilities from contracts with customers.


	June 30, 2020	December 31, 2019

Receivables	45	204
Contract liabilities	51,739	59,314

Amounts of €2,749 and €7,580 recognized in contract liabilities at the beginning of the period have been recognized as revenue during the three and six months ended June 30, 2020.

The remaining performance obligations as of June 30, 2020 are approximately €51.7 million and are expected to be recognized as revenue to a large extent over the next two years.

Disaggregation of revenue


Geographic information
	Three months	Three months	Six months	Six months
	ended	ended	ended	ended
	June 30, 2020	June 30, 2019	June 30, 2020	June 30, 2019
Revenue:
Germany	0	0	75	0
Europe	0	325	2	1,077
USA	2,934	3,683	7,992	14,284
	2,934	4,008	8,069	15,361


Major service lines
	Three months	Three months	Six months	Six months
	ended	ended	ended	ended
	June 30, 2020	June 30, 2019	June 30, 2020	June 30, 2019

Collaboration revenue	2,793	3,683	7,716	14,284
Service revenue	141	325	353	1,077
	2,934	4,008	8,069	15,361


Timing on revenue recognition
	Three months ended	Three months ended	Six months ended	Six months ended
	June 30, 2020	June 30, 2019	June 30, 2020	June 30, 2019

Point in time	106	0	283	5,633
Over time	2,828	4,008	7,786	9,728
	2,934	4,008	8,069	15,361

XML 20 R9.htm IDEA: XBRL DOCUMENT

Finance income and finance costs

6 Months Ended

Jun. 30, 2020

Finance income and finance costs

Finance income and finance costs

4. Finance income and finance costs


	Three months ended	Three months ended	Six months ended	Six months ended
	June 30, 2020	June 30, 2019	June 30, 2020	June 30, 2019
Interest SVB Loan Agreement	(59)	(128)	(116)	(283)
Foreign exchange differences	(1,022)	(728)	554	28
Finance cost lease liability	(6)	(6)	(13)	(13)
Other finance income/finance costs	71	208	166	448
Gain from the modification of SVB Loan Agreement (see note 10)	62	0	62	0
Finance income/costs - net	(954)	(654)	653	180

XML 21 R10.htm IDEA: XBRL DOCUMENT

Long term financial assets	6 Months Ended
Long term financial assets	Jun. 30, 2020
Long term financial assets
Long term financial assets	5. Long term financial assets The Company holds preferred shares in Amphivena recognized at their fair value of €3.2 million (December 31, 2019: €3.2 million). As of June 30, 2020, the fair value increased by €10 as compared to December 31, 2019 due to exchange rate differences recognized in other comprehensive income for the six months ended June 30, 2020 (2019: increase of €24). During the three months ended June 30, 2020 and 2019 the fair value decreased by €71 and €49 due to exchange rate differences.

XML 22 R11.htm IDEA: XBRL DOCUMENT

Financial assets	6 Months Ended
Financial assets	Jun. 30, 2020
Financial assets
Financial assets	6. Financial assets As of June 30, 2020 and December 31, 2019, financial assets consisted of U.S. Dollar denominated certificates of deposit with original maturities of more than three months.

XML 23 R12.htm IDEA: XBRL DOCUMENT

Equity	6 Months Ended
Equity	Jun. 30, 2020
Equity
Equity	7. Equity As of June 30, 2020 the share capital of €845 (December 31, 2019: €762) is divided into 84,493,155 (December 31, 2019: 76,249,901) common shares with a par value of €0.01 per share. In May 2020, the Company implemented an at-the-market ("ATM") program providing for the sales over time of up to $50,000,000 of its common shares. As of June 30, 2020, the Company has issued approximately 8.1 million common shares under this ATM program, generating net proceeds of approximately €21 million.

XML 24 R13.htm IDEA: XBRL DOCUMENT

Share-based payments

6 Months Ended

Jun. 30, 2020

Share-based payments

Share-based payments

8. Share-based payments

Share based payments with service condition

Share based payments with market condition

Share based payment expense

Fair value measurement

The fair value of options was determined using the Black-Scholes valuation model. The significant inputs into the valuation model of share based payment grants with service conditions are as follows (weighted average):


	June 30, 2020			June 30, 2019

Fair value at grant date	$	1.81		$	2.11
Share price at grant date	$	2.50		$	3.04
Exercise price	$	2.50		$	3.04
Expected volatility		91	%		82	%
Expected life		5.90			5.83
Expected dividends		0.00			0.00
Risk-free interest rate		1.30	%		2.14	%

Expected volatility is estimated based on the observed daily share price returns of a peer group measured over a historic period equal to the expected life of the awards.

XML 25 R14.htm IDEA: XBRL DOCUMENT

Provisions	6 Months Ended
Provisions	Jun. 30, 2020
Provisions
Provisions	9. Provisions In 2019, the group recognized costs related to the termination of the AFM 11 program totalling to €1.4 million, whereof €0.9 million were already incurred in 2019. Estimated costs expected to be incurred in future periods were recognized in provisions (€0.5 million, December 31, 2019: €0.5 million).

XML 26 R15.htm IDEA: XBRL DOCUMENT

Borrowings	6 Months Ended
Borrowings	Jun. 30, 2020
Borrowings
Borrowings	10. Borrowings Silicon Valley Bank On November 30, 2016, the Company entered into a loan agreement with Silicon Valley Bank (the “SVB loan”) which provides the Company with a senior secured term loan facility for up to €10.0 million, which agreement was amended in May 2017 to provide that such amount would be available in three tranches. In December 2016, the Company drew an initial tranche of €5.0 million and in May 2017, a second tranche of €2.5 million; the availability of a third tranche of €2.5 million expired in September 2017 with such amount remaining undrawn. Finance costs comprise the interest rate of one-month EURIBOR plus an applicable margin of 5.5%, with a floor of 5.5%, related one-time legal and arrangement fees of €236 and a final payment fee equal to 10% of the total principal amount to be paid with the last instalment. Pursuant to the loan agreement, the Company also granted the lender 166,297 and 53,395 warrants with an exercise price of $2.00 and $2.30 per share, respectively. Each warrant can be used to purchase common shares of Affimed at the respective exercise price for a period of ten years from the date of grant. The fair value of the warrants of €192 less deferred taxes and transaction costs of €81 and €8, respectively, was recorded as an addition to capital reserves in the equity of Affimed. The fair value of the warrants was determined using the Black-Scholes-Merton valuation model, with an expected volatility of 75 to 80% and an expected exercise period of five years to exercise of the warrant. The contractual maturity of the warrants is ten years. The loan is secured by a pledge of 100% of Company’s ownership interest in Affimed GmbH, all intercompany claims owed to Affimed N.V. by its subsidiaries, and collateral agreements for all bank accounts, inventory, trade receivables and other receivables of Affimed N.V. and Affimed GmbH recognized in the consolidated financial statements. As of June 30, 2020 and December 31, 2019, the fair value of the liability did not differ significantly from its carrying amount (€947 and €2,013). Repayment started in December 2017 with amortized payments of principal and interest in equal monthly instalments. In April 2020, the Company agreed with Silicon Valley Bank to extend the original maturity date of May 31, 2020 by six months to November 30, 2020. The modification resulted in a gain of €62 recognized in finance income. As of June 30, 2020, €947 (December 31, 2019: €2,013) was classified as current liabilities. UniCredit Leasing CZ In April 2019, the Group entered into a loan agreement with UniCredit Leasing CZ for €562. After an initial instalment of €127 in the second quarter of 2019, repayment is effected in monthly instalments of €8 until November 2023. As of June 30, 2020, an amount of €323 (December 31, 2019: €368) was outstanding, of which €92 was classified as current liabilities (December 31, 2019: €93). As of June 30, 2020, the fair value of the liability did not differ significantly from its carrying amount.

XML 27 R16.htm IDEA: XBRL DOCUMENT

Related parties

6 Months Ended

Jun. 30, 2020

Related parties

Related parties

11. Related parties

The following table provides the outstanding balances for management and supervisory board remuneration.


	Outstanding balances
	June 30,	December 31,
	2020	2019
Adi Hoess	0	5
Wolfgang Fischer	0	1
Dr. Thomas Hecht	19	26
Berndt Modig	9	9
Ferdinand Verdonck	11	11
Dr. Ulrich Grau	17	21
Dr. Bernhard Ehmer	16	20
Mathieu Simon	8	9

XML 28 R17.htm IDEA: XBRL DOCUMENT

Subsequent Events	6 Months Ended
Subsequent Events	Jun. 30, 2020
Subsequent Events
Subsequent Events	12. Subsequent events Upon the achievement of a clinical milestone in July 2020 under its ongoing strategic collaboration with Genentech, Affimed is eligible to receive a payment in an undisclosed amount.

XML 29 R18.htm IDEA: XBRL DOCUMENT

Basis of preparation and changes to Group's accounting policies (Policies)

6 Months Ended

Jun. 30, 2020

Basis of preparation and changes to Group's accounting policies

Statement of compliance

The interim financial statements were authorized for issuance by the management board on August 11, 2020.

Critical judgments and accounting estimates

Functional and presentation currency

Significant Accounting Policies

Significant accounting policies

New standards and interpretations applied for the first time

Standard/interpretation	Effective Date

Amendments to References to the Conceptional Framework	January 1, 2020
Amendments to IAS 1 and IAS 8: Definition of Material	January 1, 2020
Amendments to IFRS 9, IAS 39 and IFRS 7: Interest Rate Benchmark Reform	January 1, 2020
Amendments to IFRS 3 Business Combination	January 1, 2020
Amendment to IFRS 16 Leases Covid 19-Related Rent Concessions	June 1, 2020

None of the amendments to standards and new or amended interpretations had a material effect on the interim financial statements.

Fair Value Measurement

Level 1 – Prices for identical assets or liabilities quoted in active markets (non-adjusted)

Level 2 – Measurement procedures, in which the lowest level input parameter significant on the whole for fair value measurement is directly or indirectly observable for on the market

Level 3 – Measurement procedures, in which the lowest level input parameter significant on the whole for fair value measurement is not directly or indirectly observable for on the market

New standards and interpretations not yet adopted

Standard/interpretation	Effective Date

Amendments to IAS 1 Presentation of Financial Statements:
Classification of Liabilities as Current or Non-current	January 1, 2022
Amendments to IFRS 3 Business Combinations	January 1, 2022
Amendments to IAS 16 Property, Plant and Equipment	January 1, 2022
Amendments to AS 37 Provisions, Contingent Liabilities and Contingent Assets	January 1, 2022
Annual Improvements 2018-2020	January 1, 2022

XML 30 R19.htm IDEA: XBRL DOCUMENT

Basis of preparation and changes to Group's accounting policies (Tables)

6 Months Ended

Jun. 30, 2020

Basis of preparation and changes to Group's accounting policies

New standards and interpretations applied for the first time

Standard/interpretation	Effective Date

Amendments to References to the Conceptional Framework	January 1, 2020
Amendments to IAS 1 and IAS 8: Definition of Material	January 1, 2020
Amendments to IFRS 9, IAS 39 and IFRS 7: Interest Rate Benchmark Reform	January 1, 2020
Amendments to IFRS 3 Business Combination	January 1, 2020
Amendment to IFRS 16 Leases Covid 19-Related Rent Concessions	June 1, 2020

None of the amendments to standards and new or amended interpretations had a material effect on the interim financial statements.

New standards and interpretations not yet adopted

Standard/interpretation	Effective Date

Amendments to IAS 1 Presentation of Financial Statements:
Classification of Liabilities as Current or Non-current	January 1, 2022
Amendments to IFRS 3 Business Combinations	January 1, 2022
Amendments to IAS 16 Property, Plant and Equipment	January 1, 2022
Amendments to AS 37 Provisions, Contingent Liabilities and Contingent Assets	January 1, 2022
Annual Improvements 2018-2020	January 1, 2022

XML 31 R20.htm IDEA: XBRL DOCUMENT

Revenue (Tables)

6 Months Ended

Jun. 30, 2020

Revenue.

Schedule of contract liabilities from customer


	June 30, 2020	December 31, 2019

Receivables	45	204
Contract liabilities	51,739	59,314

Schedule of Disaggregation of Revenue


Geographic information
	Three months	Three months	Six months	Six months
	ended	ended	ended	ended
	June 30, 2020	June 30, 2019	June 30, 2020	June 30, 2019
Revenue:
Germany	0	0	75	0
Europe	0	325	2	1,077
USA	2,934	3,683	7,992	14,284
	2,934	4,008	8,069	15,361


Major service lines
	Three months	Three months	Six months	Six months
	ended	ended	ended	ended
	June 30, 2020	June 30, 2019	June 30, 2020	June 30, 2019

Collaboration revenue	2,793	3,683	7,716	14,284
Service revenue	141	325	353	1,077
	2,934	4,008	8,069	15,361


Timing on revenue recognition
	Three months ended	Three months ended	Six months ended	Six months ended
	June 30, 2020	June 30, 2019	June 30, 2020	June 30, 2019

Point in time	106	0	283	5,633
Over time	2,828	4,008	7,786	9,728
	2,934	4,008	8,069	15,361

XML 32 R21.htm IDEA: XBRL DOCUMENT

Finance income and finance costs (Tables)

6 Months Ended

Jun. 30, 2020

Finance income and finance costs

Finance Income and finance Costs


	Three months ended	Three months ended	Six months ended	Six months ended
	June 30, 2020	June 30, 2019	June 30, 2020	June 30, 2019
Interest SVB Loan Agreement	(59)	(128)	(116)	(283)
Foreign exchange differences	(1,022)	(728)	554	28
Finance cost lease liability	(6)	(6)	(13)	(13)
Other finance income/finance costs	71	208	166	448
Gain from the modification of SVB Loan Agreement (see note 10)	62	0	62	0
Finance income/costs - net	(954)	(654)	653	180

XML 33 R22.htm IDEA: XBRL DOCUMENT

Share-based payments (Tables)

6 Months Ended

Jun. 30, 2020

Share-based payments

Assumptions of Options Granted


	June 30, 2020			June 30, 2019

Fair value at grant date	$	1.81		$	2.11
Share price at grant date	$	2.50		$	3.04
Exercise price	$	2.50		$	3.04
Expected volatility		91	%		82	%
Expected life		5.90			5.83
Expected dividends		0.00			0.00
Risk-free interest rate		1.30	%		2.14	%

XML 34 R23.htm IDEA: XBRL DOCUMENT

Related parties (Tables)

6 Months Ended

Jun. 30, 2020


	Outstanding balances
	June 30,	December 31,
	2020	2019
Adi Hoess	0	5
Wolfgang Fischer	0	1
Dr. Thomas Hecht	19	26
Berndt Modig	9	9
Ferdinand Verdonck	11	11
Dr. Ulrich Grau	17	21
Dr. Bernhard Ehmer	16	20
Mathieu Simon	8	9

XML 35 R24.htm IDEA: XBRL DOCUMENT

Basis of preparation and changes to Group's accounting policies (Details)	6 Months Ended
	Jun. 30, 2020
Amendments To References To The Conceptional Framework
Disclosure of initial application of standards or interpretations [line items]
Standard/amendment	Amendments to References to the Conceptional Framework
Effective date for new standards and interpretations applied for the first time	Jan. 01, 2020
Amendments to IAS 1 and IAS 8: Definition of Material
Disclosure of initial application of standards or interpretations [line items]
Standard/amendment	Amendments to IAS 1 and IAS 8: Definition of Material
Effective date for new standards and interpretations applied for the first time	Jan. 01, 2020
Amendments To IFRS 9, IAS 39 And IFRS 7: Interest Rate Benchmark Reform
Disclosure of initial application of standards or interpretations [line items]
Standard/amendment	Amendments to IFRS 9, IAS 39 and IFRS 7: Interest Rate Benchmark Reform
Effective date for new standards and interpretations applied for the first time	Jan. 01, 2020
Amendments to IFRS 3 Business Combination
Disclosure of initial application of standards or interpretations [line items]
Standard/amendment	Amendments to IFRS 3 Business Combination
Effective date for new standards and interpretations applied for the first time	Jan. 01, 2020
Amendment to IFRS 16 Leases Covid 19-Related Rent Concessions [Member]
Disclosure of initial application of standards or interpretations [line items]
Standard/amendment	Amendment to IFRS 16 Leases Covid 19-Related Rent Concessions
Effective date for new standards and interpretations applied for the first time	Jun. 01, 2020

XML 36 R25.htm IDEA: XBRL DOCUMENT

Basis of preparation and changes to Group's accounting policies - New standards and interpretations not yet adopted (Details)	6 Months Ended
	Jun. 30, 2020
Amendments to IAS 1 Presentation of Financial Statements Classification of Liabilities As current or Non current
Disclosure of initial application of standards or interpretations [line items]
Standard/amendment	Classification of Liabilities as Current or Non-current
Effective date for new standards and interpretations applied for the first time	Jan. 01, 2022
Amendments to IFRS 3 Business Combinations
Disclosure of initial application of standards or interpretations [line items]
Standard/amendment	Amendments to IFRS 3 Business Combinations
Effective date for new standards and interpretations applied for the first time	Jan. 01, 2022
Amendments to IAS 16 Property, Plant and Equipment
Disclosure of initial application of standards or interpretations [line items]
Standard/amendment	Amendments to IAS 16 Property, Plant and Equipment
Effective date for new standards and interpretations applied for the first time	Jan. 01, 2022
Amendments to AS 37 Provisions, Contingent Liabilities and Contingent Assets
Disclosure of initial application of standards or interpretations [line items]
Standard/amendment	Amendments to AS 37 Provisions, Contingent Liabilities and Contingent Assets
Effective date for new standards and interpretations applied for the first time	Jan. 01, 2022
Annual Improvements 2018-2020
Disclosure of initial application of standards or interpretations [line items]
Standard/amendment	Annual Improvements 2018-2020
Effective date for new standards and interpretations applied for the first time	Jan. 01, 2022

XML 37 R26.htm IDEA: XBRL DOCUMENT

Revenue - Additional Information (Details) € in Thousands, $ in Millions	1 Months Ended		3 Months Ended		6 Months Ended			12 Months Ended
	Oct. 31, 2018 USD ($)	Oct. 31, 2018 EUR (€)	Jun. 30, 2020 EUR (€)	Jun. 30, 2019 EUR (€)	Jun. 30, 2020 USD ($)	Jun. 30, 2020 EUR (€)	Jun. 30, 2019 EUR (€)	Dec. 31, 2019 EUR (€)	Jun. 30, 2020 EUR (€)
Other revenue information
Contingent payment upon achievement of certain milestone under the collaboration agreement \| $					$ 4.4
Revenue under contract liabilities			€ 2,749			€ 7,580
Remaining performance obligations									€ 51,700
Remaining performance obligation period					2 years	2 years
Leukemia & Lymphoma Society
Other revenue information
Revenue						€ 100	€ 0
AbCheck
Other revenue information
Revenue			200	€ 300		400	1,100
Genentech Inc
Other revenue information
Revenue			€ 2,700	€ 3,700		7,600	€ 14,300
Collaboration agreement initial upfront payment received	$ 96.0	€ 83,200
Revenue under contract liabilities						€ 51,700		€ 59,300
Additional payments upon achievement of milestones \| $					$ 5,000.0

XML 38 R27.htm IDEA: XBRL DOCUMENT

Revenue (Details) - EUR (€) € in Thousands	Jun. 30, 2020	Dec. 31, 2019
Revenue.
Receivables	€ 45	€ 204
Contract liabilities	€ 51,739	€ 59,314

XML 39 R28.htm IDEA: XBRL DOCUMENT

Revenue - Disaggregation of revenue (Details) - EUR (€) € in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Other revenue information
Revenues	€ 2,934	€ 4,008	€ 8,069	€ 15,361
Point in time
Other revenue information
Revenues	106	0	283	5,633
Over time
Other revenue information
Revenues	2,828	4,008	7,786	9,728
Germany
Other revenue information
Revenues	0	0	75	0
Europe
Other revenue information
Revenues	0	325	2	1,077
USA
Other revenue information
Revenues	2,934	3,683	7,992	14,284
Collaboration
Other revenue information
Revenues	2,793	3,683	7,716	14,284
Service
Other revenue information
Revenues	€ 141	€ 325	€ 353	€ 1,077

XML 40 R29.htm IDEA: XBRL DOCUMENT

Finance income and finance costs (Details) - EUR (€) € in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Disclosure of Finance Income and Finance Costs Line Items]
Finance income/costs - net	€ (954)	€ (654)	€ 653	€ 180
Interest SVB Loan Agreement
Disclosure of Finance Income and Finance Costs Line Items]
Finance income/costs - net	(59)	(128)	(116)	(283)
Foreign exchange differences
Disclosure of Finance Income and Finance Costs Line Items]
Finance income/costs - net	(1,022)	(728)	554	28
Finance cost lease liability
Disclosure of Finance Income and Finance Costs Line Items]
Finance income/costs - net	(6)	(6)	(13)	(13)
Other finance income/finance costs - net
Disclosure of Finance Income and Finance Costs Line Items]
Finance income/costs - net	71	208	166	448
Gain from the modification of SVB Loan Agreement
Disclosure of Finance Income and Finance Costs Line Items]
Finance income/costs - net	€ 62	€ 0	€ 62	€ 0

XML 41 R30.htm IDEA: XBRL DOCUMENT

Long term financial assets (Details) - EUR (€) € in Thousands	3 Months Ended		6 Months Ended	12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Dec. 31, 2019
Disclosure of financial assets [line items]
Fair value of preferred shares				€ 3,200
Increase in fair value			€ 10	€ 24
Decrease in fair value	€ 71	€ 49
Preferred Shares
Disclosure of financial assets [line items]
Fair value of preferred shares	€ 3,200		€ 3,200

XML 42 R31.htm IDEA: XBRL DOCUMENT

Financial assets (Details)	6 Months Ended	12 Months Ended
Financial assets (Details)	Jun. 30, 2020	Dec. 31, 2019
Financial assets
Minimum Maturity period of certificate of deposits	3 months	3 months

XML 43 R32.htm IDEA: XBRL DOCUMENT

Equity (Details) - EUR (€) € / shares in Units, € in Thousands	Jun. 30, 2020	May 31, 2020	Dec. 31, 2019
Issued capital	€ 845		€ 762
Number of shares outstanding	84,493,155		76,249,901
Par value	€ 0.01		€ 0.01
Number of common shares authorized to issue at the market		50,000,000
Issued Capital
Authorized capital	€ 21,000
At-the-market sales agreement
Number of shares issued	8,100,000

XML 44 R33.htm IDEA: XBRL DOCUMENT

Share-based payments (Details)	1 Months Ended	6 Months Ended
Share-based payments (Details)	Apr. 30, 2018 D	Jun. 30, 2020 USD ($) Y $ / shares	Jun. 30, 2019 USD ($) Y $ / shares
Share-based payments
Fair value at grant date		$ 1.81	$ 2.11
Share price at grant date \| $ / shares		$ 2.50	$ 3.04
Expected volatility		91.00%	82.00%
Expected life	2	5.90	5.83
Expected dividends		$ 0.00	$ 0.00
Risk-free interest rate		1.30%	2.14%

XML 45 R34.htm IDEA: XBRL DOCUMENT

Share-based payments - Additional Information (Details) $ / shares in Units, € in Thousands, $ in Thousands	1 Months Ended		3 Months Ended		6 Months Ended				12 Months Ended
	Apr. 30, 2018 USD ($) EquityInstruments D tranche $ / shares	Apr. 30, 2018 EUR (€) EquityInstruments D tranche	Jun. 30, 2020 EUR (€) EquityInstruments shares	Jun. 30, 2019 EUR (€)	Jun. 30, 2020 EquityInstruments $ / shares	Jun. 30, 2020 EUR (€) EquityInstruments Y shares	Jun. 30, 2019 $ / shares	Jun. 30, 2019 EUR (€) Y	Dec. 31, 2019 EquityInstruments
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price					$ 2.50		$ 3.04
Number of options issued \| EquityInstruments	240,000	240,000
Number of tranches \| tranche	3	3
Trading days	15 days	15 days
Share price at grant date					$ 2.50		$ 3.04
Grant date fair value	$ 164	€ 133
Expected life	2	2				5.90		5.83
Options exercisable \| D	0	0
Share-based expense \| €			€ 684	€ 566		€ 1,410		€ 1,167
Tranche I
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share price at grant date	$ 6.15
Tranche II
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share price at grant date	8.20
Tranche III
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share price at grant date	$ 10.25
Research and Development
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share-based expense \| €			400	231		717		500
General and Administrative
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share-based expense \| €			€ 284	€ 335		€ 693		€ 667
ESOP 2014
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting period (in years)						3 years
Awards granted \| EquityInstruments			478,750			1,388,559
Awards cancelled or forfeited \| EquityInstruments			58,729			183,141
Awards outstanding \| EquityInstruments					8,315,978				7,307,567
Awards exercised \| shares			197,007			197,007
Awards vested \| EquityInstruments						5,623,642			4,773,840
Exercise period						10 years
ESOP 2014 \| Minimum
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price					$ 1.30
ESOP 2014 \| Maximum
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price					$ 13.47

XML 46 R35.htm IDEA: XBRL DOCUMENT

Provisions (Details) - EUR (€) € in Millions	12 Months Ended
Provisions (Details) - EUR (€) € in Millions	Dec. 31, 2019	Jun. 30, 2020
Provisions
Termination cost	€ 1.4
Termination cost incurred	0.9
Expected termination cost	€ 0.5	€ 0.5

XML 47 R36.htm IDEA: XBRL DOCUMENT

Borrowings - Additional Information (Details) € in Thousands		3 Months Ended		6 Months Ended
	Nov. 30, 2016 EUR (€) tranche	Jun. 30, 2020 EUR (€)	Jun. 30, 2019 EUR (€)	Jun. 30, 2020 EUR (€)	Jun. 30, 2019 EUR (€)	Dec. 31, 2019 EUR (€)	Apr. 30, 2019 EUR (€)	Dec. 31, 2018 $ / shares shares	Dec. 31, 2017 $ / shares shares	Sep. 30, 2017 EUR (€)	May 31, 2017 EUR (€)	Dec. 31, 2016 EUR (€)
Disclosure of detailed information about borrowings [line items]
Finance income/costs - net		€ (954)	€ (654)	€ 653	€ 180
Loan payable, current		947		947		€ 2,013
SVB loan
Disclosure of detailed information about borrowings [line items]
Floor rate	5.50%
Legal and arrangement fee	€ 236
Final payment fee percentage on principal	10.00%
Warrants to purchase common shares \| shares								166,297	53,395
Exercise price of share \| $ / shares								$ 2.00	$ 2.30
Expiration period	10 years
Change in fair value of warrant	€ 192
Change in deferred tax on warrant equity	81
Change in transaction cost	€ 8
Exercise period	5 years
Fair value of financial liabilities		947		947		2,013
Senior Secured Term Loan Facility
Disclosure of detailed information about borrowings [line items]
Maximum borrowing capacity	€ 10,000
Number of tranches \| tranche	3
Undrawn borrowings										€ 2,500
Senior Secured Term Loan Facility Tranche One
Disclosure of detailed information about borrowings [line items]
Borrowings												€ 5,000
Senior Secured Term Loan Facility Tranche Two
Disclosure of detailed information about borrowings [line items]
Borrowings											€ 2,500
Loan agreement with UniCredit Leasing CZ
Disclosure of detailed information about borrowings [line items]
Borrowings		323		323		368	€ 562
Loan repaid		127
Monthly repayment installment		8		8
Current liabilities		€ 92		92		€ 93
Loan agreement with UniCredit Leasing CZ
Disclosure of detailed information about borrowings [line items]
Finance income/costs - net				€ 62
EURIBOR \| SVB loan
Disclosure of detailed information about borrowings [line items]
Variable interest rate	5.50%
Minimum \| SVB loan
Disclosure of detailed information about borrowings [line items]
Volatility	75.00%
Maximum \| SVB loan
Disclosure of detailed information about borrowings [line items]
Volatility	80.00%

XML 48 R37.htm IDEA: XBRL DOCUMENT

Borrowings - Movements of Liabilities Reconcile to Cash Flows Arising from Financing Activities (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Movements of liabilities reconcile to cash flows arising from financing activities
Proceeds from borrowings	€ 0	€ 562
Repayment of borrowings	€ (1,128)	€ (1,649)

XML 49 R38.htm IDEA: XBRL DOCUMENT

Related parties - Outstanding Balances (Details) - EUR (€) € in Thousands	Jun. 30, 2020	Dec. 31, 2018
Adi Hoess
Disclosure of transactions between related parties [line items]
Key management personnel outstanding balance	€ 0	€ 5
Wolfgang Fischer
Disclosure of transactions between related parties [line items]
Key management personnel outstanding balance	0	1
Dr. Thomas Hecht
Disclosure of transactions between related parties [line items]
Key management personnel outstanding balance	19	26
Berndt Modig
Disclosure of transactions between related parties [line items]
Key management personnel outstanding balance	9	9
Ferdinand Verdonck
Disclosure of transactions between related parties [line items]
Key management personnel outstanding balance	11	11
Dr. Ulrich Grau
Disclosure of transactions between related parties [line items]
Key management personnel outstanding balance	17	21
Dr. Bernhard Ehmer
Disclosure of transactions between related parties [line items]
Key management personnel outstanding balance	16	20
Mathieu Simon
Disclosure of transactions between related parties [line items]
Key management personnel outstanding balance	€ 8	€ 9

- Details

Name:	ifrs-full_CategoriesOfRelatedPartiesAxis=afmd_MathieuSimonMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

XML 50 R39.htm IDEA: XBRL DOCUMENT

Related parties - Additional Information (Details) - EUR (€) € in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Disclosure of transactions between related parties [line items]
Share-based expense	€ 684	€ 566	€ 1,410	€ 1,167
Termination benefits			120
Supervisory Board Directors
Disclosure of transactions between related parties [line items]
Compensation received for their services	96	100	181	195
Share-based expense	17	19	53	40
Key Management Personnel Member
Disclosure of transactions between related parties [line items]
Compensation received for their services	593	708	1,198	1,414
Share-based expense	€ 361	€ 320	€ 721	€ 723

EXCEL 51 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 52 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 53 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 54 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 172 264 1 false 56 0 false 10 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.affimed.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00100 - Statement - Consolidated statements of comprehensive income / (loss) Sheet http://www.affimed.com/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss Consolidated statements of comprehensive income / (loss) Statements 2 false false R3.htm 00200 - Statement - Consolidated statements of financial position Sheet http://www.affimed.com/role/StatementConsolidatedStatementsOfFinancialPosition Consolidated statements of financial position Statements 3 false false R4.htm 00300 - Statement - Consolidated Statement of Cash Flows Sheet http://www.affimed.com/role/StatementConsolidatedStatementOfCashFlows Consolidated Statement of Cash Flows Statements 4 false false R5.htm 00400 - Statement - Consolidated Statement of Changes in Equity Sheet http://www.affimed.com/role/StatementConsolidatedStatementOfChangesInEquity Consolidated Statement of Changes in Equity Statements 5 false false R6.htm 10101 - Disclosure - Reporting entity Sheet http://www.affimed.com/role/DisclosureReportingEntity Reporting entity Notes 6 false false R7.htm 10201 - Disclosure - Basis of preparation and changes to Group's accounting policies Sheet http://www.affimed.com/role/DisclosureBasisOfPreparationAndChangesToGroupSAccountingPolicies Basis of preparation and changes to Group's accounting policies Notes 7 false false R8.htm 10301 - Disclosure - Revenue Sheet http://www.affimed.com/role/DisclosureRevenue Revenue Notes 8 false false R9.htm 10401 - Disclosure - Finance income and finance costs Sheet http://www.affimed.com/role/DisclosureFinanceIncomeAndFinanceCosts Finance income and finance costs Notes 9 false false R10.htm 10501 - Disclosure - Long term financial assets Sheet http://www.affimed.com/role/DisclosureLongTermFinancialAssets Long term financial assets Notes 10 false false R11.htm 10601 - Disclosure - Financial assets Sheet http://www.affimed.com/role/DisclosureFinancialAssets Financial assets Notes 11 false false R12.htm 10701 - Disclosure - Equity Sheet http://www.affimed.com/role/DisclosureEquity Equity Notes 12 false false R13.htm 10801 - Disclosure - Share-based payments Sheet http://www.affimed.com/role/DisclosureShareBasedPayments Share-based payments Notes 13 false false R14.htm 10901 - Disclosure - Provisions Sheet http://www.affimed.com/role/DisclosureProvisions Provisions Notes 14 false false R15.htm 11001 - Disclosure - Borrowings Sheet http://www.affimed.com/role/DisclosureBorrowings Borrowings Notes 15 false false R16.htm 11101 - Disclosure - Related parties Sheet http://www.affimed.com/role/DisclosureRelatedParties Related parties Notes 16 false false R17.htm 11201 - Disclosure - Subsequent Events Sheet http://www.affimed.com/role/DisclosureSubsequentEvents Subsequent Events Notes 17 false false R18.htm 20202 - Disclosure - Basis of preparation and changes to Group's accounting policies (Policies) Sheet http://www.affimed.com/role/DisclosureBasisOfPreparationAndChangesToGroupSAccountingPoliciesPolicies Basis of preparation and changes to Group's accounting policies (Policies) Policies 18 false false R19.htm 30203 - Disclosure - Basis of preparation and changes to Group's accounting policies (Tables) Sheet http://www.affimed.com/role/DisclosureBasisOfPreparationAndChangesToGroupSAccountingPoliciesTables Basis of preparation and changes to Group's accounting policies (Tables) Tables http://www.affimed.com/role/DisclosureBasisOfPreparationAndChangesToGroupSAccountingPolicies 19 false false R20.htm 30303 - Disclosure - Revenue (Tables) Sheet http://www.affimed.com/role/DisclosureRevenueTables Revenue (Tables) Tables http://www.affimed.com/role/DisclosureRevenue 20 false false R21.htm 30403 - Disclosure - Finance income and finance costs (Tables) Sheet http://www.affimed.com/role/DisclosureFinanceIncomeAndFinanceCostsTables Finance income and finance costs (Tables) Tables http://www.affimed.com/role/DisclosureFinanceIncomeAndFinanceCosts 21 false false R22.htm 30803 - Disclosure - Share-based payments (Tables) Sheet http://www.affimed.com/role/DisclosureShareBasedPaymentsTables Share-based payments (Tables) Tables http://www.affimed.com/role/DisclosureShareBasedPayments 22 false false R23.htm 31103 - Disclosure - Related parties (Tables) Sheet http://www.affimed.com/role/DisclosureRelatedPartiesTables Related parties (Tables) Tables http://www.affimed.com/role/DisclosureRelatedParties 23 false false R24.htm 40201 - Disclosure - Basis of preparation and changes to Group's accounting policies (Details) Sheet http://www.affimed.com/role/DisclosureBasisOfPreparationAndChangesToGroupSAccountingPoliciesDetails Basis of preparation and changes to Group's accounting policies (Details) Details http://www.affimed.com/role/DisclosureBasisOfPreparationAndChangesToGroupSAccountingPoliciesTables 24 false false R25.htm 40202 - Disclosure - Basis of preparation and changes to Group's accounting policies - New standards and interpretations not yet adopted (Details) Sheet http://www.affimed.com/role/DisclosureBasisOfPreparationAndChangesToGroupSAccountingPoliciesNewStandardsAndInterpretationsNotYetAdoptedDetails Basis of preparation and changes to Group's accounting policies - New standards and interpretations not yet adopted (Details) Details 25 false false R26.htm 40301 - Disclosure - Revenue - Additional Information (Details) Sheet http://www.affimed.com/role/DisclosureRevenueAdditionalInformationDetails Revenue - Additional Information (Details) Details 26 false false R27.htm 40302 - Disclosure - Revenue (Details) Sheet http://www.affimed.com/role/DisclosureRevenueDetails Revenue (Details) Details http://www.affimed.com/role/DisclosureRevenueTables 27 false false R28.htm 40303 - Disclosure - Revenue - Disaggregation of revenue (Details) Sheet http://www.affimed.com/role/DisclosureRevenueDisaggregationOfRevenueDetails Revenue - Disaggregation of revenue (Details) Details 28 false false R29.htm 40401 - Disclosure - Finance income and finance costs (Details) Sheet http://www.affimed.com/role/DisclosureFinanceIncomeAndFinanceCostsDetails Finance income and finance costs (Details) Details http://www.affimed.com/role/DisclosureFinanceIncomeAndFinanceCostsTables 29 false false R30.htm 40501 - Disclosure - Long term financial assets (Details) Sheet http://www.affimed.com/role/DisclosureLongTermFinancialAssetsDetails Long term financial assets (Details) Details http://www.affimed.com/role/DisclosureLongTermFinancialAssets 30 false false R31.htm 40601 - Disclosure - Financial assets (Details) Sheet http://www.affimed.com/role/DisclosureFinancialAssetsDetails Financial assets (Details) Details http://www.affimed.com/role/DisclosureFinancialAssets 31 false false R32.htm 40701 - Disclosure - Equity (Details) Sheet http://www.affimed.com/role/DisclosureEquityDetails Equity (Details) Details http://www.affimed.com/role/DisclosureEquity 32 false false R33.htm 40801 - Disclosure - Share-based payments (Details) Sheet http://www.affimed.com/role/DisclosureShareBasedPaymentsDetails Share-based payments (Details) Details http://www.affimed.com/role/DisclosureShareBasedPaymentsTables 33 false false R34.htm 40802 - Disclosure - Share-based payments - Additional Information (Details) Sheet http://www.affimed.com/role/DisclosureShareBasedPaymentsAdditionalInformationDetails Share-based payments - Additional Information (Details) Details 34 false false R35.htm 40901 - Disclosure - Provisions (Details) Sheet http://www.affimed.com/role/DisclosureProvisionsDetails Provisions (Details) Details http://www.affimed.com/role/DisclosureProvisions 35 false false R36.htm 41001 - Disclosure - Borrowings - Additional Information (Details) Sheet http://www.affimed.com/role/DisclosureBorrowingsAdditionalInformationDetails Borrowings - Additional Information (Details) Details 36 false false R37.htm 41002 - Disclosure - Borrowings - Movements of Liabilities Reconcile to Cash Flows Arising from Financing Activities (Details) Sheet http://www.affimed.com/role/DisclosureBorrowingsMovementsOfLiabilitiesReconcileToCashFlowsArisingFromFinancingActivitiesDetails Borrowings - Movements of Liabilities Reconcile to Cash Flows Arising from Financing Activities (Details) Details 37 false false R38.htm 41101 - Disclosure - Related parties - Outstanding Balances (Details) Sheet http://www.affimed.com/role/DisclosureRelatedPartiesOutstandingBalancesDetails Related parties - Outstanding Balances (Details) Details 38 false false R39.htm 41102 - Disclosure - Related parties - Additional Information (Details) Sheet http://www.affimed.com/role/DisclosureRelatedPartiesAdditionalInformationDetails Related parties - Additional Information (Details) Details 39 false false All Reports Book All Reports afmd-20200630.xml afmd-20200630.xsd afmd-20200630_cal.xml afmd-20200630_def.xml afmd-20200630_lab.xml afmd-20200630_pre.xml http://xbrl.ifrs.org/taxonomy/2019-03-27/ifrs-full http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/srt/2019-01-31 http://xbrl.sec.gov/country/2017-01-31 true true ZIP 56 0001104659-20-092988-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-20-092988-xbrl.zip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end